



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|   |   |   |
|---|---|---|
| <p>(51) International Patent Classification <sup>6</sup> :<br/>A61K 39/02, C12P 21/06, 21/04, C07H 21/04</p>  | <p>A1</p>   | <p>(11) International Publication Number: <b>WO 99/25376</b></p> <p>(43) International Publication Date: 27 May 1999 (27.05.99)</p> |
| <p>(21) International Application Number: PCT/US98/24357</p> <p>(22) International Filing Date: 13 November 1998 (13.11.98)</p> <p>(30) Priority Data:<br/>08/972,902 18 November 1997 (18.11.97) US</p> <p>(71) Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA [US/US]; Suite 300, 3700 Market Street, Philadelphia, PA 19104-3147 (US).</p> <p>(72) Inventors: FRANKEL, Fred, R.; 435 West Allens Lane, Philadelphia, PA 19119 (US). PORTNOY, Daniel, A.; 1196 Curtis Street, Albany, CA 94706 (US).</p> <p>(74) Agents: LEARY, Kathryn, Doyle et al.; Panitch Schwarze Jacobs &amp; Nadel, P.C., 22nd floor, One Commerce Square, 2005 Market Street, Philadelphia, PA 19103-7086 (US).</p> | <p>(81) Designated States: AU, CA, CN, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p><b>Published</b><br/><i>With international search report.</i></p> |   |
| <p>(54) Title: BACTERIAL VACCINES COMPRISING AUXOTROPHIC, ATTENUATED STRAINS OF <i>LISTERIA</i> EXPRESSING HETEROLOGOUS ANTIGENS</p> <p>(57) Abstract</p> <p>The invention includes auxotrophic attenuated mutants of <i>Listeria</i> and methods of their use as vaccines.</p>   |   |   |

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |  |    |  |    |                          |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania                  | ES | Spain                                    | LS | Lesotho                                      | SI | Slovenia                 |
| AM | Armenia                  | FI | Finland                                  | LT | Lithuania                                    | SK | Slovakia                 |
| AT | Austria                  | FR | France                                   | LU | Luxembourg                                   | SN | Senegal                  |
| AU | Australia                | GA | Gabon                                    | LV | Latvia                                       | SZ | Swaziland                |
| AZ | Azerbaijan               | GB | United Kingdom                           | MC | Monaco                                       | TD | Chad                     |
| BA | Bosnia and Herzegovina   | GE | Georgia                                  | MD | Republic of Moldova                          | TG | Togo                     |
| BB | Barbados                 | GH | Ghana                                    | MG | Madagascar                                   | TJ | Tajikistan               |
| BE | Belgium                  | GN | Guinea                                   | MK | The former Yugoslav<br>Republic of Macedonia | TM | Turkmenistan             |
| BF | Burkina Faso             | GR | Greece                                   | ML | Mali   | TR | Turkey                   |
| BG | Bulgaria                 | HU | Hungary                                  | MN | Mongolia                                     | TT | Trinidad and Tobago      |
| BJ | Benin                    | IE | Ireland                                  | MR | Mauritania                                   | UA | Ukraine                  |
| BR | Brazil                   | IL | Israel                                   | MW | Malawi                                       | UG | Uganda                   |
| BY | Belarus                  | IS | Iceland                                  | MX | Mexico                                       | US | United States of America |
| CA | Canada                   | IT | Italy                                    | NE | Niger  | UZ | Uzbekistan               |
| CF | Central African Republic | JP | Japan                                    | NL | Netherlands                                  | VN | Viet Nam                 |
| CG | Congo                    | KE | Kenya                                    | NO | Norway                                       | YU | Yugoslavia               |
| CH | Switzerland              | KG | Kyrgyzstan                               | NZ | New Zealand                                  | ZW | Zimbabwe                 |
| CI | Côte d'Ivoire            | KP | Democratic People's<br>Republic of Korea | PL | Poland                                       |    |                          |
| CM | Cameroon                 | KR | Republic of Korea                        | PT | Portugal                                     |    |                          |
| CN | China                    | KZ | Kazakstan                                | RO | Romania                                      |    |                          |
| CU | Cuba                     | LC | Saint Lucia                              | RU | Russian Federation                           |    |                          |
| CZ | Czech Republic           | LI | Liechtenstein                            | SD | Sudan  |    |                          |
| DE | Germany                  | LK | Sri Lanka                                | SE | Sweden                                       |    |                          |
| DK | Denmark                  | LR | Liberia                                  | SG | Singapore                                    |    |                          |
| EE | Estonia                  |    |  |    |  |    |                          |

BACTERIAL VACCINES COMPRISING AUXOTROPHIC, ATTENUATED STRAINS OF *LISTERIA* EXPRESSING HETEROLOGOUS ANTIGENS

GOVERNMENT SUPPORT

This invention was supported in part by funds from the U.S.

5 Government (NIH Grant Nos. AI-26919 and AI-27655) and the U.S. Government may therefore have certain rights in the invention.

FIELD OF THE INVENTION

The invention relates to vaccine vectors comprising bacteria.

BACKGROUND OF THE INVENTION

10 The use of vaccines is a cost-effective medical tool for the management of infectious diseases, including infectious diseases caused by bacteria, viruses, parasites, and fungi. In addition to effecting protection against infectious diseases, vaccines may now also be developed which stimulate the host's immune system to intervene in tumor growth.

15 Host immune responses include both the humoral immune response involving antibody production and the cell-mediated immune response. Protective immunization via vaccine has usually been designed to induce the formation of humoral antibodies directed against infectious agents, tumor cells, or the action of toxins. However, the control of certain diseases characterized by the presence of tumor  
20 cells or by chronic infection of cells with infectious agents, often requires a cell-mediated immune response either in place of, or in addition to the generation of antibody. While the humoral immune response may be induced using live infectious agents and agents which have been inactivated, a cellular immune response is most effectively induced through the use of live agents as vaccines. Such live agents include  
25 live infectious agents which may gain access to the cytoplasm of host cells where the

proteins encoded by these agents are processed into epitopes which when presented to the cellular immune system, induce a protective response.

Microorganisms, particularly *Salmonella* and *Shigella* which have been attenuated using a variety of mechanisms, have been examined for their ability to encode and express heterologous antigens (Coynault et al., 1996, Mol. Microbiol. 22:149-160; Noriega et al., 1996, Infect. Immun. 64:3055-3061; Brett et al., 1993, J. Immunol. 150:2869-2884; Fouts et al., 1995, Vaccine 13:1697-1705, Sizemore et al., 1995, Science 270:299-302). Such bacteria may be useful as live attenuated bacterial vaccines which serve to induce a cellular immune response directed against a desired heterologous antigen.

*Listeria monocytogenes* (*L. monocytogenes*) is the prototypic intracellular bacterial pathogen which elicits a predominantly cellular immune response when inoculated into an animal (Kaufmann, 1993, Ann. Rev. Immunol. 11:129-163). When used as a vector for the transmission of genes encoding heterologous antigens derived from infectious agents or derived from tumor cells, recombinant *Listeria* encoding and expressing an appropriate heterologous antigen have been shown to successfully protect mice against challenge by lymphocytic choriomeningitis virus (Shen et al., 1995, Proc. Natl. Acad. Sci. USA 92:3987-3991; Goossens et al., 1995, Int. Immunol. 7:797-802) and influenza virus (Ikonomidis et al., 1997, Vaccine 15:433-440). Further, heterologous antigen expressing recombinant *Listeria* have been used to protect mice against lethal tumor cell challenge (Pan et al., 1995, Nat. Med. 1:471-477; Paterson and Ikonomidis, 1996, Curr. Opin. Immunol. 8:664-669). In addition, it is known that a strong cell-mediated immune response directed against HIV-1 gag protein may be induced in mice infected with a recombinant *L. monocytogenes* comprising HIV-1 gag (Frankel et al., 1995, J. Immunol. 155:4775-4782).

Although the potential broad use of *Listeria* as a vaccine vector for the prevention and treatment of infectious disease and cancer has significant advantages over other vaccines, the issue of safety during use of *Listeria* is not trivial. The use of the most common strain of *Listeria*, *L. monocytogenes*, is accompanied by potentially

severe side effects, including the development of listeriosis in the inoculated animal. This disease, which is normally food-borne, is characterized by meningitis, septicemia, abortion and often a high rate of mortality in infected individuals. While natural infections by *L. monocytogenes* are fairly rare and may be readily controlled by a number of antibiotics, the organism may nevertheless be a serious threat in immunocompromised or pregnant patients. One large group individuals that might benefit from the use of *L. monocytogenes* as a vaccine vector are individuals who are infected with HIV. However, because these individuals are severely immunocompromised as a result of their infection, the use of *L. monocytogenes* as a vaccine vector is undesirable unless the bacteria are fully and irreversibly attenuated.

There is a need for the development of a strain of *L. monocytogenes* for use as a vaccine in and of itself and for use as a bacterial vaccine vector which is attenuated to the extent that it is unable to cause disease in an individual into whom it is inoculated. The present invention satisfies this need.

## SUMMARY OF THE INVENTION

The invention includes a method of eliciting a T cell immune response to an antigen in a mammal comprising administering to the mammal an auxotrophic attenuated strain of *Listeria* which expresses the antigen, wherein the auxotrophic attenuated strain comprises a mutation in at least one gene whose protein product is essential for growth of the *Listeria*. In a preferred embodiment, the *Listeria* is *L. monocytogenes*. In another preferred embodiment, the auxotrophic attenuated strain is auxotrophic for the synthesis of D-alanine. In addition, the mutation comprises a mutation in both the *dal* and the *dat* genes of the *Listeria*.

In one aspect of the invention, the auxotrophic attenuated strain further comprises DNA encoding a heterologous antigen, or the the auxotrophic attenuated strain further comprises a vector comprising a DNA encoding a heterologous antigen.

The heterologous antigen may be an HIV-1 antigen.

The invention also includes a vaccine comprising an auxotrophic attenuated strain of *Listeria* which expresses an antigen, wherein the auxotrophic attenuated strain comprises a mutation in at least one gene whose protein product is essential for growth of the *Listeria*.

5 In preferred embodiments, the *Listeria* is *L. monocytogenes*. In other preferred embodiments, the auxotrophic attenuated strain is auxotrophic for the synthesis of D-alanine. In yet other preferred embodiments, the mutation comprises a mutation in both the *dal* and the *dat* genes of the *Listeria*.

10 The auxotrophic attenuated strain may further comprise DNA encoding a heterologous antigen or a vector comprising a DNA encoding a heterologous antigen.

The heterologous antigen may be an HIV-1 antigen.

Also included in the invention is an isolated nucleic acid sequence comprising a portion of a *Listeria dal* gene and an isolated nucleic acid sequence comprising a portion of a *Listeria dat* gene.

15 In addition, the invention includes an isolated strain of *Listeria* comprising a mutation in a *dal* gene and a mutation in a *dat* gene which render the strain auxotrophic for D-alanine. In one aspect, the isolated strain of *Listeria* further comprises a heterologous antigen.

#### BRIEF DESCRIPTION OF THE DRAWINGS

20 **Figure 1**, comprising Figures 1A, 1B, and 1C, is the DNA sequence of the *L. monocytogenes* alanine racemase gene (*dal*) of *L. monocytogenes* and the amino acid sequence encoded thereby. The lysyl residue involved in the binding of pyridoxal-P is indicated by an asterisk.

25 **Figure 2**, comprising Figures 2A and 2B, depicts the linear alignment of the deduced amino acid sequences of the alanine racemases of *L. monocytogenes* (LMDAL), *B. stearothermophilus*, (BSTDAL), and *B. subtilis* (BSUBDAL). Identical amino acids are boxed.

**Figure 3**, comprising Figures 3A, 3B, and 3C, is the DNA sequence of the *L. monocytogenes* D-amino acid aminotransferase gene (*dat*) and the amino acid sequence encoded thereby. The lysyl residue involved in the binding of pyridoxal-P is indicated by an asterisk.

5                   **Figure 4**, comprising Figure 4A and 4B, depicts the linear alignment of the deduced amino acid sequences of the D-amino acid aminotransferases of *L. monocytogenes* (LMDAT), *S. haemolyticus* (SHAEDAT), *B. sphaericus* (BSPHDAT), and *Bacillus* species YM-1 (BSPDAT). Identical amino acids are boxed.

10                   **Figure 5** is a graph depicting the growth requirement for D-alanine of the *dal<sup>-</sup>dat<sup>-</sup>* double mutant strain of *L. monocytogenes*. The *dal<sup>-</sup>dat<sup>-</sup>* (*daldat*) and wild-type (*L. monocytogenes*+) strains of *L. monocytogenes* were grown in liquid culture in BHI medium at 37°C in the presence (+D-ala) or absence (-D-ala) of exogenous D-alanine (100 µg/ml). In additional experiments, the mutant cell culture was also provided D-alanine after 30 minutes and after 60 minutes.

15                   **Figure 6** is a series of images of light micrographs depicting the growth of wild-type *L. monocytogenes* (Panel A) and the *dal<sup>-</sup>dat<sup>-</sup>* double mutant strain of *L. monocytogenes* (Panel B) in J774 macrophages at 5 hours after infection with about 5 bacteria per mouse cell. Panel C illustrates an infection by double mutant bacteria in the continuous presence of D-alanine (80 µg/ml). Arrowheads point to some mutant  
20                   bacteria.

**Figure 7**, comprising figures 7A, 7B, and 7C is a series of graphs depicting infection of mammalian cells with the *dal<sup>-</sup>dat<sup>-</sup>* double mutant (open circles) and wild-type strains of *L. monocytogenes* (closed circles). Mammalian cells which were infected included J774 murine macrophage-like cells (Panel A), primary murine  
25                   bone marrow macrophages (Panel B), and human epithelial cells (HeLa) (Panel C). Panel A also depicts mutant infection in the presence of D-alanine (100 µg/ml) (closed squares) and in the presence of D-alanine from 0 to 4 hrs during infection (open squares).

**Figure 8** is a series of images of photomicrographs depicting the association of actin with intracytoplasmic wild-type *L. monocytogenes* (Panel A: 2 hours; Panel B: 5 hours) or with the *dal<sup>-</sup> dat<sup>-</sup>* double mutant of *L. monocytogenes* (Panel C: 2 hours wherein D-alanine was present from 0 to 30 minutes; Panel D: 5 hours, wherein D-alanine was present from 0 to 30 minutes; Panel E: 5 hours, wherein D-alanine was present continuously), following infection of J744 cells with these bacteria. The images on the top row illustrate the binding of FITC-labeled anti-Listerial antibodies to total bacteria, while the bottom row illustrates the binding of TRITC-labeled phalloidin to actin. The arrowheads point to some bacteria associated with actin.

**Figure 9** is a graph depicting the protection of BALB/c mice against challenge with ten times the LD<sub>50</sub> of wild-type *L. monocytogenes* by immunization with the *dal<sup>-</sup> dat<sup>-</sup>* double mutant strain of *L. monocytogenes*. Groups of 5 mice were immunized with the following organisms: (1)  $4 \times 10^2$  wild-type *L. monocytogenes*, (2)  $2 \times 10^7$  *dal<sup>-</sup> dat<sup>-</sup>* (+D-alanine supplement), (3)  $2 \times 10^5$  *dal<sup>-</sup> dat<sup>-</sup>* (+D-alanine supplement), (4)  $2 \times 10^4$  *dal<sup>-</sup> dat<sup>-</sup>* (+D-alanine supplement), (5)  $2 \times 10^2$  *dal<sup>-</sup> dat<sup>-</sup>* mutant *dal<sup>-</sup> dat<sup>-</sup>* (no D-alanine supplement). Mice were challenged 21-28 days after immunization. Log<sub>10</sub> protection was calculated as described in the Examples.

**Figure 10** is a graph depicting the recovery of bacteria from spleens of BALB/c mice following sublethal infection with wild type *L. monocytogenes* (closed circles), the *dal<sup>-</sup> dat<sup>-</sup>* mutant in the absence of D-alanine (open circles), and the *dal<sup>-</sup> dat<sup>-</sup>* mutant in the presence of 20 mg D-alanine (open squares). The points at day 0 illustrate the total number of organisms injected, not the number of bacteria per spleen.

**Figure 11**, comprising Figures 11A and 11B, is two graphs depicting the cytolytic activity of splenocytes isolated from mice at 10-14 days after infection with in Figure 11A, wild type *L. monocytogenes*(●○), or naive control (■□). Figure 11B, *dal<sup>-</sup> dat<sup>-</sup>* mutant:  $3 \times 10^7$  bacteria (Δ);  $3 \times 10^7$  bacteria with boost at 10 days (Δ);  $3 \times 10^7$  bacteria wherein animals were provided D-alanine subcutaneously (●○);  $3 \times 10^7$  bacteria plus 2 mg/ml D-alanine (■) or 0.2 mg/ml D-alanine in drinking water (▲).



## DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to vaccines comprising attenuated strains of *Listeria*, wherein the bacteria have been attenuated by the introduction of auxotrophic mutations in the *Listeria* genomic DNA. These strains are herein referred to as attenuated auxotrophic strains or "AA strains" of *Listeria*.

It has been discovered in the present invention that the administration of an AA strain of *Listeria* to a mammal results in the development of a host cytotoxic T cell (CTL) response directed against *Listeria* following survival of the AA strain in the mammal for a time sufficient for the development of the response. The AA strain provides protection against challenge by *L. monocytogene* and is therefore suitable for use in a vaccine for protection against infection by this organism. The AA strain of the invention may thus be employed as a vaccine for the prevention and/or treatment of infection by *Listeria*. In addition, the AA strain of the invention may have added to it a heterologous gene wherein the gene is expressed by the AA strain. Such AA strains encoding additional heterologous genes are useful as bacterial vector vaccines for the prevention and/or treatment of infection caused by any number of infectious agents and for the prevention and/or treatment of tumors in mammals.

AA strains of *Listeria* that are auxotrophic for D-alanine are contemplated as part of this invention.

By the term "auxotrophic for D-alanine", as used herein, is meant that the AA strain of *Listeria* is unable to synthesize D-alanine in that it cannot grow in the absence of D-alanine and therefore requires exogenously added D-alanine for growth.

D-alanine is required for the synthesis of the peptidoglycan component of the cell wall of virtually all bacteria, and is found almost exclusively in the microbial world. Wild-type *Listeria* species synthesize D-alanine and thus do not require exogenously added D-alanine for growth. An AA strain of *L. monocytogenes* has been discovered in the present invention which is unable to synthesize D-alanine. This organism may be grown in the laboratory but is incapable of growth outside the laboratory in unsupplemented environments, including in the cytoplasm of eukaryotic

host cells, the natural habitat of this organisms during infection. Such strains of *Listeria* are useful as vaccines.

By the term "vaccine," as used herein, is meant a population of bacteria which when inoculated into a mammal has the effect of stimulating a cellular immune response comprising a T cell response. The T cell response may be a cytotoxic T cell response directed against macromolecules produced by the bacteria. However, the induction of a T cell response comprising other types of T cells by the vaccine of the invention is also contemplated. For example, *Listeria* infection also induces both CD4+ T cells and CD8+ T cells. Induced CD4+ T cells are responsible for the synthesis of cytokines, such as interferon- $\gamma$ , IL-2 and TNF- $\alpha$ . CD8+ T cells may be cytotoxic T cells and also secrete cytokines such as interferon- $\gamma$  and TNF- $\alpha$ . All of these cells and the molecules synthesized therein play a role in the infection and subsequent protection of the host against *Listeria*. Cytokines produced by these cells activate additional T cells and also macrophages and recruit polymorphonuclear leukocytes to the site of infection.

Both prophylactic and therapeutic vaccines are contemplated as being within the scope of the present invention, that is, vaccines which are administered either prior to or subsequent to the onset of disease are included in the invention.

D-alanine auxotrophic mutants useful as vaccine vectors may be generated in a number of ways. As described in the Examples presented herein, disruption of one of the alanine racemase gene (*dal*) or the D-amino acid aminotransferase gene (*dat*), each of which is involved in D-alanine synthesis, did not result in a bacterial strain which required exogenously added D-alanine for growth. However, disruption of both the *dal* gene and the *dat* gene generated an AA strain of *Listeria* which required exogenously added D-alanine for growth.

The generation of AA strains of *Listeria* deficient in D-alanine synthesis may be accomplished in a number of ways that are well known to those of skill in the art, including deletion mutagenesis, insertion mutagenesis, and mutagenesis which results in the generation of frameshift mutations, mutations which effect premature

5 termination of a protein, or mutation of regulatory sequences which affect gene expression. Mutagenesis can be accomplished using recombinant DNA techniques or using traditional mutagenesis technology using mutagenic chemicals or radiation and subsequent selection of mutants. Deletion mutants are preferred because of the accompanying low probability of reversion of the auxotrophic phenotype. Mutants of D-alanine which are generated according to the protocols presented herein may be tested for the ability to grow in the absence of D-alanine in a simple laboratory culture assay. Those mutants which are unable to grow in the absence of this compound are selected for further study.

10 In addition to the aforementioned D-alanine associated genes, other genes involved in D-alanine synthesis may be used as targets for mutagenesis of *Listeria*. Such genes include, but are not limited to any other known or heretofore unknown D-alanine associated genes.

15 Genes which are involved in the synthesis of other metabolic components in a bacterial cell may also be useful targets for the generation of attenuated auxotrophic mutants of *Listeria*, which mutants may also be capable of serving as bacterial vaccine vectors for use in the methods of the present invention. The generation and characterization of such other AA strains of *Listeria* may be accomplished in a manner similar to that described herein for the generation of D-alanine deficient AA strains of *Listeria*.

20 Additional potential useful targets for the generation of additional auxotrophic strains of *Listeria* include the genes involved in the synthesis of the cell wall component D-glutamic acid. To generate D-glutamic acid auxotrophic mutants, it is necessary to inactivate the *dat* gene, which is involved in the conversion of D-glu + pyr to alpha-ketoglutarate + D-ala and the reverse reaction. It is also necessary to inactivate the glutamate racemase gene, *dga*. Other potential useful targets for the generation of additional auxotrophic strains of *Listeria* are the genes involved in the synthesis of diamimopimelic acid. In this instance, a gene encoding aspartate beta-

semialdehyde dehydrogenase may be inactivated (Sizemore et al., 1995, Science 270:299-302).

By the term "attenuation," as used herein, is meant a diminution in the ability of the bacterium to cause disease in an animal. In other words, the pathogenic characteristics of the attenuated *Listeria* strain have been lessened compared with wild-type *Listeria*, although the attenuated *Listeria* is capable of growth and maintenance in culture. Using as an example the intravenous inoculation of Balb/c mice with an attenuated *Listeria*, the lethal dose at which 50% of inoculated animals survive ( $LD_{50}$ ) is preferably increased above the  $LD_{50}$  of wild-type *Listeria* by at least about 10-fold, more preferably by at least about 100-fold, more preferably at least about 1,000 fold, even more preferably at least about 10,000 fold, and most preferably at least about 100,000-fold. An attenuated strain of *Listeria* is thus one which does not kill an animal to which it is administered, or is one which kills the animal only when the number of bacteria administered is vastly greater than the number of wild type non-attenuated bacteria which would be required to kill the same animal. An attenuated bacterium should also be construed to mean one which is incapable of replication in the general environment because the nutrient required for its growth is not present therein. Thus, the bacterium is limited to replication in a controlled environment wherein the required nutrient is provided. The attenuated strains of the present invention are therefore environmentally safe in that they are incapable of uncontrolled replication.

It is believed that any *Listeria* species capable of infectious disease may be genetically attenuated according to the methods of the present invention to yield a useful and safe bacterial vaccine, provided the attenuated *Listeria* species exhibits an  $LD_{50}$  in a host organism that is significantly greater than that of the non-attenuated wild type species. Thus, strains of *Listeria* other than *L. monocytogenes* may be used for the generation of attenuated mutants for use as vaccines. Preferably, the *Listeria* strain useful for the generation of attenuated vaccines is *L. monocytogenes*.

An AA strain of *Listeria* may be generated which encodes and expresses a heterologous antigen. The heterologous antigen encoded by the AA strain of *Listeria*

is one which when expressed by *Listeria* is capable of providing protection in an animal against challenge by the infectious agent from which the heterologous antigen was derived, or which is capable of affecting tumor growth and metastasis in a manner which is of benefit to a host organism. Heterologous antigens which may be  
5 introduced into an AA strain of *Listeria* by way of DNA encoding the same thus include any antigen which when expressed by *Listeria* serves to elicit a cellular immune response which is of benefit to the host in which the response is induced. Heterologous antigens therefore include those specified by infectious agents, wherein an immune response directed against the antigen serves to prevent or treat disease  
10 caused by the agent. Such heterologous antigens include, but are not limited to, viral, bacterial, fungal or parasite surface proteins and any other proteins, glycoproteins, lipoprotein, glycolipids, and the like. Heterologous antigens also include those which provide benefit to a host organism which is at risk for acquiring or which is diagnosed as having a tumor. The host organism is preferably a mammal and most preferably, is  
15 a human.

By the term "heterologous antigen," as used herein, is meant a protein or peptide, a glycoprotein or glycopeptide, a lipoprotein or lipopeptide, or any other macromolecule which is not normally expressed in *Listeria*, which substantially corresponds to the same antigen in an infectious agent, a tumor cell or a tumor-related  
20 protein. The heterologous antigen is expressed by an AA strain of *Listeria*, and is processed and presented to cytotoxic T-cells upon infection of mammalian cells by the AA strain. The heterologous antigen expressed by *Listeria* species need not precisely match the corresponding unmodified antigen or protein in the tumor cell or infectious agent so long as it results in a T-cell response that recognizes the unmodified antigen or  
25 protein which is naturally expressed in the mammal.

By the term "tumor-related antigen," as used herein, is meant an antigen which affects tumor growth or metastasis in a host organism. The tumor-related antigen may be an antigen expressed by a tumor cell, or it may be an antigen which is

expressed by a non-tumor cell, but which when so expressed, promotes the growth or metastasis of tumor cells.

The types of tumor antigens and tumor-related antigens which may be introduced into *Listeria* by way of incorporating DNA encoding the same, include any  
5 known or heretofore unknown tumor antigen.

The heterologous antigen useful in vaccine development may be selected using knowledge available to the skilled artisan, and many antigenic proteins which are expressed by tumor cells or which affect tumor growth or metastasis or which are expressed by infectious agents are currently known. For example, viral  
10 antigens which may be considered as useful as heterologous antigens include but are not limited to the nucleoprotein (NP) of influenza virus and the gag protein of HIV. Other heterologous antigens include, but are not limited to, HIV env protein or its component parts gp120 and gp41, HIV nef protein, and the HIV pol proteins, reverse transcriptase and protease. In addition, other viral antigens such as herpesvirus proteins  
15 may be useful. The heterologous antigens need not be limited to being of viral origin. Parasitic antigens, such as, for example, malarial antigens, are included, as are fungal antigens, bacterial antigens and tumor antigens.

As noted herein, a number of proteins expressed by tumor cells are also known and should be included in the list of heterologous antigens which may be  
20 inserted into the vaccine strain of the invention. These include, but are not limited to, the bcr/abl antigen in leukemia, HPVE6 and E7 antigens of the oncogenic virus associated with cervical cancer, the MAGE1 and MZ2-E antigens in or associated with melanoma, and the MVC-1 and HER-2 antigens in or associated with breast cancer.

The introduction of DNA encoding a heterologous antigen into a strain  
25 of *Listeria* may be accomplished, for example, by the creation of a recombinant *Listeria* in which DNA encoding the heterologous antigen is harbored on a vector, such as a plasmid for example, which plasmid is maintained and expressed in the *Listeria* species. Alternatively, DNA encoding the heterologous antigen may be stably integrated into the *Listeria* chromosome by employing, for example, transposon

mutagenesis or by homologous recombination. A preferred method for producing recombinant *Listeria* having a gene encoding a heterologous antigen integrated into the chromosome thereof, is the induction of homologous recombination between a temperature sensitive plasmid comprising DNA encoding the antigen and *Listeria* chromosomal DNA. Stable transformants of *Listeria* which express the desired antigen may be isolated and characterized as described herein in the experimental examples. This method of homologous recombination is advantageous in that site directed insertion of DNA encoding the heterologous antigen is effected, thereby minimizing the possibility of disruption of other areas of the *Listeria* chromosome which may be essential for growth of this organism.

Several approaches may be employed to express the heterologous antigen in *Listeria* species as will be understood by one skilled in the art once armed with the present disclosure. Genes encoding heterologous antigens are preferably designed to either facilitate secretion of the heterologous antigen from the bacterium or to facilitate expression of the heterologous antigen on the *Listeria* cell surface.

While the heterologous antigen preferably comprises only a desired antigen along with appropriate signal sequences and the like, also contemplated in the invention is a fusion protein which comprises the desired heterologous antigen and a secreted or cell surface protein of *Listeria*. Listerial proteins which are suitable components of such fusion proteins include, but are not limited to, listeriolysin O (LLO) and phosphatidylinositol-specific phospholipase (PI-PLC). A fusion protein may be generated by ligating the genes which encode each of the components of the desired fusion protein, such that both genes are in frame with each other. Thus, expression of the ligated genes results in a protein comprising both the heterologous antigen and the listerial protein. Expression of the ligated genes may be placed under the transcriptional control of a listerial promoter/regulatory sequence such that expression of the gene is effected during growth and replication of the organism. Signal sequences for cell surface expression and/or secretion of the fused protein may

also be added to genes encoding heterologous antigens in order to effect cell surface expression and/or secretion of the fused protein.

When the heterologous antigen is used alone (i.e., in the absence of fused *Listeria* sequences), it may be advantageous to fuse thereto signal sequences for cell surface expression and/or secretion of the heterologous antigen. The procedures for accomplishing this are well known in the art of bacteriology and molecular biology.

The DNA encoding the heterologous antigen which is expressed in the vaccine strain of the invention must be preceded by a suitable promoter to facilitate such expression. The appropriate promoter/regulatory and signal sequences to be used will depend on the type of listerial protein desired in the fusion protein and will be readily apparent to those skilled in the art of listeria molecular biology. For example, preferred *L. monocytogenes* promoter/regulatory and/or signal sequences which may be used to direct expression of a fusion protein include, but are not limited to, sequences derived from the *Listeria hly* gene which encodes LLO, the *Listeria p60* gene (Bouwer et al., 1996, Infect. Immun. 64:2515-2522) and possibly the *Listeria actA* gene which encodes a surface protein necessary for *L. monocytogenes* actin assembly. Other promoter sequences which might be useful in some circumstances include the *plcA* gene which encodes PI-PLC, the listeria *mpl* gene, which encodes a metalloprotease, the listeria *plcB* gene encoding a phospholipase C, and the listeria *inlA* gene which encodes internalin, a listeria membrane protein. For a review of genes involved in *L. monocytogenes* pathogenesis, see Portnoy et al. (1992, Infect. and Immun. 60:1263-1267). It is also contemplated as part of this invention that heterologous regulatory elements such as promoters derived from phage and promoters or signal sequences derived from other bacterial species may be employed for the expression of a heterologous antigen by the *Listeria* species.

Examples of the use of recombinant *L. monocytogenes* strains that express a heterologous antigen for induction of an immune response against tumor cell antigens or infectious agent antigens are described in U.S. Patent Application Nos.



08/366,372 and 08/366,477, respectively. The disclosures of these two patent applications are hereby incorporated herein by reference.

The data presented herein indicate that certain AA strains of *Listeria* may undergo osmotic lysis following infection of a host cell. Thus, if the *Listeria* which is introduced into the host cell comprises a vector, the vector is released into the cytoplasm of the host cell. The vector may comprise DNA encoding a heterologous antigen. Uptake into the nucleus of the vector DNA enables transcription of the DNA encoding the heterologous antigen and subsequent expression of the antigen in and/or secretion of the same from the infected host cell. Typically, the vector is a plasmid that is capable of replication in *Listeria*. The vector may encode a heterologous antigen, wherein expression of the antigen is under the control of eukaryotic promoter/regulatory sequences. Typical plasmids having suitable promoters that might be employed include, but are not limited to, pCMVbeta comprising the immediate early promoter/enhancer region of human cytomegalovirus, and those which include the SV40 early promoter region or the mouse mammary tumor virus LTR promoter region.

Thus, it is also contemplated as part of the present invention that AA strains of *Listeria* may be employed as a vaccine for the purpose of stimulating a CTL immune response against an infectious agent or a tumor cell, wherein the AA strain comprises a vector encoding a heterologous antigen that may be expressed using a eukaryotic expression system. According to the invention, the vector is propagated in the AA strain of *Listeria* concomitant with the propagation of the AA strain itself. The vector may be, for example, a plasmid that is capable of replication in the AA strain or the vector may be lysogenic phage. The vector must contain a prokaryotic origin of replication and must not contain a eukaryotic origin of replication in order that the vector is capable of replication in a prokaryotic cell but, for safety reasons, is rendered absolutely incapable of replication in eukaryotic cells.

A cytotoxic T-cell response in a mammal is defined as the generation of cytotoxic T-cells capable of detectably lysing cells presenting an antigen against which the T cell response is directed. Preferably, within the context of the present invention,

the T cell response is directed against a heterologous antigen expressed in an AA strain of *Listeria* or which is expressed by a vector which is delivered to a cell via *Listeria* infection. Assays for a cytotoxic T-cell response are well known in the art and include, for example, a chromium release assay (Frankel et al., 1995, J. Immunol. 155:4775-4782). In addition to a chromium release assay, an assay for released lactic acid dehydrogenase may be performed using a Cytotox 96 kit obtained from Promega Biotech, WI.

In preferred embodiments and using a chromium release assay, at an effector cell to target cell ratio of about 50:1, the percentage of target cell lysis is preferably at least about 10% above the background level of cell lysis. The background level of cell lysis is the percent lysis of cells which do not express the target antigen. More preferably, the percentage of target cell lysis is at least about 20% above background; more preferably, at least about 40% above background; more preferably, at least about 60% above background; and most preferably, at least about 70% above background.

The vaccines of the present invention may be administered to a host vertebrate animal, preferably a mammal, and more preferably a human, either alone or in combination with a pharmaceutically acceptable carrier. The vaccine is administered in an amount effective to induce an immune response to the *Listeria* strain itself or to a heterologous antigen which the *Listeria* species has been modified to express. The amount of vaccine to be administered may be routinely determined by one of skill in the art when in possession of the present disclosure. A pharmaceutically acceptable carrier may include, but is not limited to, sterile distilled water, saline, phosphate buffered solutions or bicarbonate buffered solutions. The pharmaceutically acceptable carrier selected and the amount of carrier to be used will depend upon several factors including the mode of administration, the strain of *Listeria* and the age and disease state of the vaccinee. Administration of the vaccine may be by an oral route, or it may be parenteral, intranasal, intramuscular, intravascular, intrarectal, intraperitoneal, or any one of a variety of well-known routes of administration. The route of administration

may be selected in accordance with the type of infectious agent or tumor to be treated. The vaccines of the present invention may be administered in the form of elixirs, capsules or suspensions for oral administration or in sterile liquids for parenteral or intravascular administration. The vaccine may also be administered in conjunction  
5 with a suitable adjuvant, which adjuvant will be readily apparent to the skilled artisan.

The immunogenicity of the AA strain of the invention may be enhanced in several ways. For example, a booster inoculation following the initial inoculation may be used to induce an enhanced CTL response directed against the AA strain.

In another approach, transient suppression of the auxotrophic phenotype  
10 of the AA strain is accomplished by providing the AA strain with the required nutrient for a period of time shortly before, after, or concomitant with administration of the *Listeria* vaccine to the host. The organism will replicate for the brief period during which the nutrient is present, after which, upon exhaustion of the supply of the nutrient, the organism will cease replication. This brief period of controlled replication will  
15 serve to provide more organisms in the host in a manner similar to that of natural infection by *Listeria*, which should stimulate an enhanced CTL response directed against the organism and antigens expressed thereby.

In yet another approach, the use of a suicide plasmid may be employed to conditionally suppress the attenuation of the *Listeria* AA strain by temporarily  
20 supplying the missing enzyme or enzymes to the bacterium for synthesis of the essential nutrient. A suitable suicide plasmid includes pKSV7, the same plasmid which was used to mediate insertion of genes into the *Listeria* chromosome as described herein. This plasmid contains a gram positive (for use in *Listeria*), temperature-sensitive replication system such that growth at 37-40°C inhibits plasmid replication in  
25 *Listeria*. This plasmid also contains an *E. coli* replication system which is not temperature-sensitive (Smith et al., 1992, *Biochimie* 74:705-711). The plasmid, or even more temperature-sensitive derivatives thereof, may be further modified by inserting an alanine racemase gene into the plasmid, which modified plasmid is then inserted into an AA strain of *Listeria*. *Listeria* cells having the plasmid inserted

therein, are replicated at 30°C for a short period of time in order that some molecules of racemase are accumulated in the cytoplasm. The *Listeria* cells, so replicated are then injected into an animal or a human, wherein plasmid replication then ceases because of the temperature sensitive nature of the replication system at 37°C. Essentially, the cells would divide only a few times until the available racemase becomes diluted out, wherein the cells would cease replication altogether and become attenuated again. To ensure even tighter temperature sensitive replication, a temperature sensitive promoter may be used to regulate expression of the racemase gene and/or temperature sensitive mutations may be created in the racemase gene itself.

For treatment of cancer, the vaccine of the invention may be used to protect people at high risk for cancer. In addition, the vaccine may be used as an immunotherapeutic agent for the treatment of cancer following debulking of tumor growth by surgery, conventional chemotherapy, or radiation treatment. Patients receiving such treatment may be administered a vaccine which expresses a desired tumor antigen for the purpose of generating a CTL response against any residual tumor cells in the individual. The vaccine of the present invention may also be used to inhibit the growth of any previously established tumors in a human by either eliciting a CTL response directed against the tumor cells *per se*, or by eliciting a CTL response against cells which synthesize tumor promoting factors, wherein such a CTL response serves to kill those cells thereby diminishing or ablating the growth of the tumor.

The vaccine of the invention may be maintained in storage until use. Storage may comprise freezing the vaccine, or maintaining the vaccine at 4°C, room temperature, or the vaccine may first be lyophilized and then stored.

The invention particularly contemplates administration of a vaccine to a human for the purpose of preventing, alleviating, or ablating HIV infection. The protocol which is described herein for the administration of a vaccine to a human for the purpose of treating HIV infection is provided as an example of how to administer an attenuated auxotrophic *Listeria* strain as a vaccine to a human. This protocol should not be construed as being the only protocol which can be used, but rather, should be

construed merely as an example of the same. Other protocols will become apparent to those skilled in the art when in possession of the present invention.

Essentially, an auxotrophic strain of *L. monocytogenes* which requires D-alanine for growth is constructed as described in the examples. The mutant is constructed by generating deletion mutations in both the *dal* gene and the *dat* gene, essentially following the procedures of Camilli et al., (1993, Mol. Microbiol. 8:143-157). The mutant strain is then modified using recombinant DNA techniques to express an HIV-1 antigen, preferably an antigenic portion of the gag protein, essentially as described in Frankel et al. (1995, J. Immunol. 155:4775-4778). A human is then immunized by injecting a solution containing the auxotrophic *L. monocytogenes* strain and a supplement of D-alanine.

One of ordinary skill in the art will know the quantities of cells and D-alanine which should be administered to the human based upon a knowledge of the dosages provided herein which are administered to mice. For example, in BALB/c mice,  $10^7$  cells and 20 mg of D-alanine are the preferred dosages. Subsequent injections of the modified *L. monocytogenes* cells and D-alanine may also be given to boost the immune response.

Other HIV-1 antigens or proteins that may be used to generate a vaccine in accordance with this invention are the HIV env protein or its component parts, gp120 and gp 41, HIV gag, HIV nef and HIV pol or its component parts, reverse transcriptase and protease.

Isolated nucleic acid sequences encoding the *dal* gene and the *dat* gene of *L. monocytogenes* are also contemplated as part of this invention. In addition to their utility in generating deletion mutants of *L. monocytogenes* as disclosed herein, these isolated nucleic acid sequences encoding the *dal* gene and the *dat* gene may be used as probes and primers in identifying homologous genes in other *Listeria* species using PCR and other hybridization technology available in the art and described, for example, in Sambrook, et al. (1989, In: Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York; Innis et al., ed., 1990, In: PCR Protocols,

Academic Press, Inc., San Diego). Additionally, the isolated nucleic acid sequences encoding *dal* or *dat* may be used to construct a suicide plasmid that expresses one or both of the genes. The suicide plasmid(s) may be used to complement the D-alanine *Listeria* auxotrophs for a limited time after immunization as disclosed herein.

5           An "isolated nucleic acid", as used herein, refers to a nucleic acid sequence, a DNA or an RNA or fragment thereof which has been separated from the sequences which flank it in a naturally occurring state, *e.g.*, a DNA fragment which has been removed from the sequences which are normally adjacent to the fragment, *e.g.*, the sequences adjacent to the fragment in a genome in which it naturally occurs. The  
10 term also applies to nucleic acids which have been substantially purified from other components which naturally accompany the nucleic acid, *e.g.*, RNA or DNA or proteins, which naturally accompany it in the cell. The term therefore includes, for example, a recombinant DNA which is incorporated into a vector; into an  
15 autonomously replicating plasmid or virus; or into the genomic DNA of a prokaryote or eukaryote; or which exists as a separate molecule (*e.g.*, as a cDNA or a genomic or cDNA fragment produced by PCR amplification, restriction enzyme digestion or chemical synthesis) independent of other sequences. It also includes a recombinant DNA which is part of a hybrid gene encoding additional polypeptide sequence.

20           Typically probes and primers for use in identifying other *dal* and *dat* genes will comprise a portion of a *Listeria dal* or *dat* gene that is at least about 15 consecutive nucleotides. More typically, a probe or primer comprises a portion of at least about 20, even more typically, at least about 30 and even more typically, at least about 40 consecutive nucleotides of a *dal* or *dat* gene of *Listeria*.

25           In other related aspects, the invention includes a vectors which comprises an isolated nucleic acid encoding *dal* or *dat* and which is preferably capable of directing expression of the protein encoded by the nucleic acid in a vector-containing cell. The invention further includes cells comprising a vector encoding *dal* or *dat*, including both prokaryotic and eukaryotic cells.

The isolated nucleic acids of the invention should be construed to include an RNA or a DNA sequence specifying the *dal* gene or the *dat* gene, and any modified forms thereof, including chemical modifications of the DNA or RNA which render the nucleotide sequence more stable when it is cell free or when it is associated with a cell. Chemical modifications of nucleotides may also be used to enhance the efficiency with which a nucleotide sequence is taken up by a cell or the efficiency with which it is expressed in a cell. Any and all combinations of modifications of the nucleotide sequences are contemplated in the present invention.

The invention should not be construed as being limited solely to the DNA and amino acid sequences shown in Figures 1 and 3. Once armed with the present invention, it is readily apparent to one skilled in the art that any other DNA and encoded amino acid sequence of the *dal* and *dat* genes of other *Listeria* species may be obtained by following the procedures described herein. The invention should therefore be construed to include any and all *dal* and *dat* DNA sequence and corresponding amino acid sequence, having substantial homology to the *dal* and *dat* DNA sequence, and the corresponding amino acid sequence, shown in Figures 1 and 3, respectively. Preferably, DNA which is substantially homologous is about 50% homologous, more preferably about 70% homologous, even more preferably about 80% homologous and most preferably about 90% homologous to the *dal* or *dat* DNA sequence shown in Figures 1 and 3, respectively. Preferably, an amino acid sequence which is substantially homologous is about 50% homologous, more preferably about 70% homologous, even more preferably about 80% homologous and most preferably about 90% homologous to the amino acid sequences encoded by the *dal* and *dat* genes shown in Figures 1 and 3, respectively.

"Homologous" as used herein, refers to the subunit sequence similarity between two polymeric molecules, *e.g.*, between two nucleic acid molecules, *e.g.*, two DNA molecules or two RNA molecules, or between two polypeptide molecules. When a subunit position in both of the two molecules is occupied by the same monomeric subunit, *e.g.*, if a position in each of two DNA molecules is occupied by adenine, then

they are homologous at that position. The homology between two sequences is a direct function of the number of matching or homologous positions, e.g., if half (e.g., five positions in a polymer ten subunits in length) of the positions in two compound sequences are homologous then the two sequences are 50% homologous, if 90% of the positions, e.g., 9 of 10, are matched or homologous, the two sequences share 90% homology. By way of example, the DNA sequences 3'ATTGCC5' and 3'TATGCG5' share 50% homology.

The invention is further described in detail by reference to the following experimental examples. These examples are provided for purposes of illustration only, and are not intended to be limiting unless otherwise specified. Thus, the invention should in no way be construed as being limited to the following examples, but rather, should be construed to encompass any and all variations which become evident as a result of the teaching provided herein.

The experimental examples described herein provide procedures and results which establish that attenuated auxotrophic mutants of *L. monocytogenes* are useful as vaccines for eliciting a CTL response.

Materials and Methods useful in the construction and use of an attenuated auxotrophic *L. monocytogenes* strain are now described.

Bacteria and plasmids. The *L. monocytogenes* strain 10403S (Portnoy et al., 1988, *supra*) comprises the wild-type organism used in these studies. This organism was propagated in brain/heart infusion medium (BHI) (Difco Labs). *L. monocytogenes* strain 10403S has an LD<sub>50</sub> of approximately 3 X 10<sup>4</sup> when injected intravenously or intraperitoneally into BALB/c mice (Schafer et al., 1992, J. Immunol. 149:53-59).

*E. coli* DH5a was used for cloning. This organism was propagated in Luria broth (Sambrook et al., 1989, *supra*). The plasmid pKSV7, which was used for allelic exchange reactions in *L. monocytogenes*, is a shuttle vector capable of replication in *E. coli*, where it is selected in the presence of 50 µg of ampicillin per ml of media, and in *L. monocytogenes*, wherein replication of the plasmid is temperature



sensitive and is selected in the presence of 10  $\mu$ g of chloramphenicol per ml of media (Smith et al., 1992, Biochimie 74:705-711). Plasmid DNA obtained from *E coli* and total DNA (chromosomal and plasmid) from obtained from *Listeria monocytogenes* were isolated using standard methods (Sambrook et al., 1989, *supra*).

5                    Identification of D-alanine synthesis genes in *L. monocytogenes* by  
homology with D-alanine synthesis genes in other gram positive organisms. Based on  
sequences of the alanine racemase gene (*dal*) in gram-positive organisms (Ferrari et al.,  
1985, Bio/technology 3:1003-1007; Tanizawa et al., 1988, Biochemistry 27:1311-  
1316), primers were designed which corresponded to two 20 base consensus sequences  
10 from highly conserved regions at the 5' and 3' ends of the *dal* gene. These primers  
were modified to reflect the preferred codon usage in *Listeria*. These primers were  
used in a PCR reaction using chromosomal DNA from either *L. monocytogenes* or *B.*  
*subtilis* as templates. A similar sized PCR product (850 nucleotides) was obtained  
from both *L. monocytogenes* and *B. subtilis*. Analysis of the 850 nucleotide PCR  
15 product from the *Listeria* template, and the amino acid sequence encoded thereby,  
indicated substantial homology with the alanine racemase genes of the other gram-  
positive organisms.

A similar strategy was used to identify and sequence a portion of a D-  
amino acid aminotransferase gene (*dat*) of *Listeria*, based on sequences in *B.*  
20 *sphaericus*, *B. species* YM-1 (Tanizawa et al., 1989, *supra*), and Pucci et al., 1995, J.  
Bacteriol. 177:336-342). Primers based on *dat* sequence in the other gram positive  
organisms was used for PCR amplification of *L. monocytogenes* DNA and a PCR  
product of about 400 nucleotides was obtained. Analysis of the DNA sequence of the  
400 nucleotide PCR product, and the amino acid sequence encoded thereby, indicated  
25 substantial homology with the aminotransferase genes of the other gram positive  
organisms.

Strategy for sequence determination of the complete genes. The  
sequence of the remaining portions of the *L. monocytogenes dal* gene adjoined to the 5'  
and 3' ends of the central PCR product was determined using anchored PCR reactions

(Rubin et al., 1993, Proc. Natl. Acad. Sci. USA 90:9280-9284). Briefly, this procedure utilized a *Bgl*III-restriction digest (for the 5' portion of the gene) or a *Xba*I digest (for the 3' portion of the gene) of *Listeria* chromosomal DNA. The ends of the digested *Listeria* chromosomal DNA were then ligated to a small fragment of DNA containing the T7 promoter. A 5'-portion PCR product and a 3'-portion PCR product were then made and sequenced using primers from within the central *dal* gene PCR product and a second primer homologous to the T7 promoter fragment. This procedure permitted determination of the entire sequence of the *dal* gene.

The sequence of the remainder of the *dat* gene was determined by use of an inverse PCR reaction (Collins et al., 1984, Proc. Natl. Acad. Sci. USA 81:6812-6816; Triglia et al., 1988, Nucl. Acids Res. 16:8186). Briefly, a *Hind*III digest of *Listeria* chromosomal DNA was permitted to self-ligate under conditions of low DNA concentration so that mainly single circular molecules would form. Outward-directing primers with homologies at the two ends of the original PCR segment of the gene were then used to make a new PCR product that began at the 5'-end of the original PCR segment, proceeded to the 5'-end of the gene through the *Hind*III self-ligation site and into the 3' - end of the gene. Using this method, the entire *dat* gene sequence was obtained.

Production of mutations in *Listeria dal* and *dat* genes. The *dal* gene was inactivated by means of a double allelic exchange reaction following the protocol of Camilli et al. (Camilli et al., 1993, Mol. Microbiol 8:143-157). A *ts* shuttle plasmid pKSV7 (Smith et al., 1992, *supra*) construct containing an erythromycin gene (Shaw and Clewell, 1985, J. Bacteriol. 164:782-796) situated between a 450-base pair fragment of the 5' end of the 850-base pair *dal* gene PCR product and a 450-base pair fragment of the 3' end of the *dal* gene PCR product was introduced into *Listeria* to produce a double allelic exchange reaction between the chromosomal *dal* gene and the plasmid pKSV7 *dal* construct. A *dal* deletion mutant covering about 25% of the gene in the region of its active site was obtained.

The chromosomal *dat* gene of *L. monocytogenes* was also inactivated using a double allelic exchange reaction. A pKSV7 plasmid construct containing 450-base pair fragments corresponding to the 5' and 3' ends of the *dat* gene PCR product, which had been joined together by an appropriate PCR reaction, was introduced into  
5 *Listeria*. A double allelic exchange reaction between the chromosomal *dat* gene and the *dat* plasmid construct resulted in the deletion of 30% of the central bases of the *dat* gene.

Infection of Cells in Culture. To examine the intracellular growth of the attenuated strain of *Listeria* in cell culture, monolayers of J774 cells, a murine  
10 macrophage-like cell line, primary murine bone marrow macrophages, and the human HeLa cell line, were grown on glass coverslips and infected as described (Portnoy et al., 1988, *supra*). To enhance the efficiency of infection of HeLa cells, a naturally non-phagocytic cell line, the added bacteria were centrifuged onto the HeLa cells at 543 x g for 15 minutes. At various times after infection, samples of the cultures were obtained  
15 in order to perform differential staining for the determination of viable intracellular bacteria, or for immunohistochemical analysis.

Immunohistochemistry. Coverslips with attached infected macrophages or HeLa cells were washed with PBS, and the cells were fixed in 3.2% formalin and permeabilized using 0.05% Tween 20. *Listeria* were detected using rabbit anti-*Listeria*  
20 O antiserum (Difco Laboratories) followed by LSRSC-labeled donkey anti-rabbit antibodies or coumarin-labeled goat anti-rabbit antibodies. Actin was detected using FITC- or TRITC-labeled phalloidin. To distinguish extracellular (or phagosomal) from intracytoplasmic bacteria, the former were stained prior to permeabilization of the cells.

Induction of listeriolysin O-specific CTLs. Female BALB/c mice, 6 to  
25 8 weeks of age (Charles River Laboratories, Raleigh, NC) were immunized by intraperitoneal inoculation with either wild-type or *dal dat* strains of *L. monocytogenes*. After 14 days, some of the mice were boosted with a second inoculation containing the same number of microorganisms as were given in the first inoculation. Ten or more days after the last inoculation,  $6 \times 10^7$  splenocytes obtained

from a given animal were incubated in Iscove's modified DMEM with  $3 \times 10^7$  splenocytes from that same animal that had been loaded with  $10 \mu\text{M}$  listeriolysin O (LLO) peptide 91-99 during a 60 minute incubation at  $37^\circ\text{C}$ . After five days of *in vitro* stimulation, the resulting cultures were assayed for the presence of CTL activity capable of recognizing LLO-peptide-labeled P815 cells following previously published procedures (Wipke et al., 1993, Eur. J. Immunol. 23:2005-2010; Frankel et al., 1995, *supra*). Every determination of lytic activity was corrected for activity in unlabeled target cells, which exhibited between 1 and 10 percent lysis.

Animal protection studies. Female BALB/c mice (Bantin-Klingman, Fremont, CA) at 8 weeks of age were immunized with approximately  $0.1 \text{ LD}_{50}$  of viable wild-type *L. monocytogenes* or the *dal'dar* double mutant strain in 0.2 ml of vehicle, by tail vein injection. Three to four weeks following immunization, groups of four to five mice each were challenged with approximately  $10 \text{ LD}_{50}$  of viable wild-type *L. monocytogenes* strain 10403 in 0.2 ml of vehicle, by tail vein injection. Spleens were removed from the mice 48 hours later and were homogenized individually in 4.5 ml PBS-1% proteose-peptone using a tissue homogenizer (Tekmar). The homogenates were serially diluted and plated onto BHI agar.  $\text{Log}_{10}$  protection was determined by subtracting the mean of the  $\text{log}_{10}$  CFU/spleen values of the test group from the mean of the  $\text{log}_{10}$  CFU/spleen values of the normal control group.

Construction of an Auxotrophic Attenuated Strain of *L. monocytogenes* Useful as a Vaccine: Construction of an attenuated strain of *L. monocytogenes* defective in cell wall synthesis

*L. monocytogenes* was examined to determine whether the bacteria harbor genes for the synthesis of D-alanine. The alanine racemase (*dal*) gene, used by many microorganisms for the synthesis of D-alanine, has been sequenced in *Salmonella* (Galakatos et al., 1986, Biochemistry 25:3255-3260; Wasserman et al., 1984, Biochemistry 23:5182-5187), *B. subtilis* (Ferrari et al., 1985, Bio/technology 3:1003-1007), and *B. stearothermophilis* (Tanizawa et al., 1988, Biochemistry 27:1311-1316), but the gene has not been reported in *Listeria*. Primers based on the

sequences (adjusted for preferred codon usage in *Listeria*) of two highly conserved regions of the *dal* gene in two different gram-positive organisms were employed in a PCR reaction performed on *L. monocytogenes* chromosomal DNA to search for evidence of the *dal* gene in *Listeria*. A product that exhibited significant homology  
5 with the published *dal* gene sequences was obtained. The sequence of the remainder of the *L. monocytogenes dal* gene was determined as described herein and is depicted in Figure 1. The translated protein sequence is compared with alanine racemases of the other gram-positive organisms in Figure 2.

The *dal* gene was inactivated by an in-frame insertion of a 1.35 kb  
10 fragment of DNA encoding erythromycin resistance at an *SpeI* site near the center of the gene. The resulting *dal*<sup>-</sup> bacteria were found to grow both in rich bacteriological medium (BHI) as well as in a synthetic medium in the presence or absence of D-alanine. Mutation of the *dal* gene was also achieved by an in-frame deletion covering 82% of the gene with the same effect.

15 A second enzyme used by some bacteria for synthesis of D-alanine is D-amino acid aminotransferase, encoded by the *dat* gene (Tanizawa et al., 1989, J. Biol. Chem. 264:2450-2454; Pucci et al., 1995, J. Bacteriol. 177:336-342). Following the same strategy used to detect the *dal* gene in *L. monocytogenes*, a PCR product that exhibited significant sequence homology with known *dat* genes and gene products was  
20 obtained. The sequence obtained from the PCR product was only the partial gene sequence, and remainder of the *dat* gene sequence (as depicted in Figure 3) was determined according to procedures described herein. The deduced protein sequence of the *L. monocytogenes dat* gene is compared with other *dat* gene products in Figure 4.

The *L. monocytogenes dat* gene was inactivated by in-frame deletion of  
25 31% of its central region. The growth of the resulting *dat*<sup>-</sup> bacteria in various bacteriological media was again found to be independent of the presence of D-alanine.

A double mutant strain of *L. monocytogenes, dal*<sup>-</sup>*dat*<sup>-</sup>1, was produced by a double allelic exchange reaction between the erythromycin-resistant *dal*<sup>-</sup> organism and the shuttle vector carrying the *dat* gene deletion. The growth of the double mutant

in bacteriological media was found to be completely dependent on the presence of D-alanine (Figure 5). A double mutant containing deletions in both of the genes, designated *dal'dar-12*, had the same phenotype. The growth of the double-deletion strain in the absence of D-alanine could be complemented by a plasmid carrying the *dal* gene of *B. subtilis*. All of the *dal'dar* double mutant experiments reported in the following examples employed the *dal'dar-1* double mutant.

Expression of the defective phenotype following infection of eukaryotic cells

To determine whether a defect in the ability of *L. monocytogenes* to synthesize D-alanine would be expressed as an inability to replicate in the cytoplasm of eukaryotic cells because of the absence of the required D-alanine in the cytoplasm, several different cell lines and primary cells in culture were infected with the wild-type and mutant strains of this organism.

J774 cells are a mouse macrophage-like cell line that readily take up *L. monocytogenes* by phagocytosis and permit its cytoplasmic growth following escape of the bacteria from the phagolysosome (Tilney et al., 1989, J. Cell Biol. 109:1597-1608). Figure 6 depicts typical J774 cells as observed at 5 hours after infection with about 5 bacteria per cell of either wild-type *Listeria* (Panel A) or the double *dal'dar* mutant *Listeria* (Panel B). Whereas large numbers of bacteria were observed to be associated with mouse cells infected with wild-type *Listeria*, few were seen following infection with the double mutant bacteria. Infection by double mutant bacteria in culture medium containing D-alanine permitted bacterial growth which was indistinguishable from that seen in cells infected with wild type *Listeria* (Figure 6, Panel C).

Some J774 cells contained small round darkly-staining objects, often in pairs, that may be spheroblast-like bacteria, although they were not examined further. When these cells were infected at higher multiplicities (a multiplicity of infection of about 1-10), many cells contained multiple microorganisms, but the double mutant again failed to multiply. Most double mutant-infected cells possessed pychnotic nuclei

and a pale cytoplasm and presumably were dead; mouse cells harboring wild-type *Listeria* did not exhibit this property at any time after infection.

To quantify some of these observations, the number of intracellular bacteria (defined by gentamicin resistance) that could form colonies on medium containing D-alanine was enumerated at several times after infection (Figure 7). The data clearly demonstrate that the double mutant was unable to replicate in J774 cells, and in fact slowly died during the course of the experiment. The data also illustrate that the replication-defective phenotype of the double mutant was suppressed by the inclusion of D-alanine (at 100  $\mu\text{g/ml}$ ) in the tissue culture medium at the time of infection. This suppression was reversed within 2 hours after removal of the D-alanine. The phenotype of the mutant bacteria was also examined in mouse bone marrow-derived macrophages and in the HeLa cell line of human epithelial cells. It was determined that the double mutant was unable to replicate in either of these cell types as well (Figure 7, Panels B and C).

It was again observed that double-mutant-infected macrophages possessed pyknotic nuclei more frequently than did macrophages infected with wild-type bacteria. Infection of bone marrow macrophages was employed to examine the intracytoplasmic status of the bacteria. Within a few hours after infection of cells by *L. monocytogenes*, when the bacteria have escaped from the phagosome, host actin filaments form a dense cloud around the intracytoplasmic bacteria, and then rearrange to form a polarized comet tail which propels the bacteria through the cytoplasm (Tilney et al., 1989, *supra*). The actin can readily be visualized using appropriately labeled anti-*Listeria* antibodies. At 2 hours post-infection using a multiplicity of infection of about 5 bacteria per cell, 25% of wild type bacteria associated with J774 macrophages were surrounded with a halo of stained actin (Figure 8, Panel A), and at 5 hours, virtually 100% of infected cells exhibited actin staining, some cells having long actin tails (Figure 8, Panel B). However, the staining of actin in double-mutant infected macrophages was much rarer (less than 2%) when compared with wild type infected cells. Nevertheless, if D-alanine was present during only the 30 minute period of

bacterial adsorption, at 2 hours post-infection ' 22% of the mutant cell-associated bacteria were surrounded with actin (Figure 8, Panel C); at 5 hours, this number of intracytoplasmic bacteria had risen to only 27% (Figure 8, Panel D). If D-alanine was present during the entire infection period (Figure 8, Panel E), the result observed in these cells at 5 hours was indistinguishable from those observed in wild type infected cells.

Since J774 cells have long been culture adapted and reflect very few of the normal properties of tissue macrophages, the entry of mutant bacteria into the cytosol of primary bone marrow macrophages which had been in culture for only 6 days was examined. Because these cells demonstrate the high bacterial killing capacity of normal macrophages, they were infected at a ratio of about 50 bacteria per cell. Under these conditions, at 2 hours after infection, 6.8% of the double mutant bacteria were found to be associated with actin in these cells, and this number increased to the same level as that observed after wild type infection (19%) by the inclusion of D-alanine for the first 30 minutes of the infection (18.2%) or for the entire period of infection (19.4%). Therefore, depending on the cell type examined, mutant bacteria in the absence of D-alanine either exhibited a very low or moderate efficiency of entering the host cytosol, or exhibited reduced binding of actin onto their surface. However, the brief presence of D-alanine during the initial phase of infection allowed a normal fraction of bacteria to enter the cytosol and bind actin.

#### Induction of an immune response using the attenuated bacteria

Infection of mice with *L. monocytogenes* produces a long-lived state of specific immunologic memory that enables the infected host to resist lethal challenge by the same organism for months following the primary infection. To determine whether infection of mice with sub-lethal doses of the double mutant could induce this important long lasting state of immunity, the following experiments were performed.

Mice were injected intravenously with  $2 \times 10^7$  ( $<0.05$  LD<sub>50</sub>) of the double mutant and were challenged 3 to 4 weeks later with 10 LD<sub>50</sub> of wild type *L. monocytogenes*. D-alanine (20 mg) was provided in the initial inoculum of mutant



organisms to be certain that the organisms were fully viable at the time of initial infection (this had the effect of reducing the LD<sub>50</sub> about 10 fold). The data presented in Figure 9 demonstrate that the level of antilisterial protection was approximately 3 log<sub>10</sub> following a single infection by the mutant bacteria, a similar level of protection to that generated by immunization with the wild-type organism. The same dose of mutant bacteria injected without D-alanine provided little protection.

To determine whether the high degree of protection generated by the mutant bacteria could be accounted for by their survival and replication in the infected mice, the spleens of infected animals were removed and the number of surviving mutant bacteria was assessed. In Figure 10 there is shown evidence which indicates that in the absence of D-alanine, few mutant organisms survived for more than one day after infection; the presence of D-alanine in the initial inoculum permitted a few bacteria to survive longer. Importantly, the almost complete protection obtained using mutant bacteria occurred in spite of the fact that by 2 days post-infection more than 100-fold fewer bacteria were detected in the spleens of mutant infected mice compared with wild type infected animals.

Listerolysin O peptide 91-99 is the major epitope of the listerolysin O protein and one of the major epitopes to which mice respond when mounting a cell mediated immune response against infection with *L. monocytogenes* (Bouwer et al., 1996, Infect. Immun. 64:2515-2522; Harty et al., 1992, J. Exp. Med. 175:1531-1538; Pamer et al., 1991, Nature 353:852-855). To determine whether the protective immunity generated by infection with the *dal dat* double mutant strain of *L. monocytogenes* was associated with the induction of cytolytic T cells, splenocytes obtained from infected animals were assayed for their ability to lyse target cells loaded with this peptide. In Figure 11 there is shown the fact that animals that were infected intraperitoneally with 3 x 10<sup>7</sup> and were provided D-alanine subcutaneously both before and after infection exhibited strong CTL responses directed against the LLO peptide. Likewise, mice provided with D-alanine in their drinking water before and after infection mounted a modest CTL response after single infection with 3 x 10<sup>7</sup> mutant

bacteria. In the absence of D-alanine, animals infected with and boosted one time with  $3 \times 10^7$  bacteria, also exhibited a modest CTL response to LLO peptide 91-99. Single infection with  $3 \times 10^7$  of the double mutant bacteria in the absence of D-alanine produced no significant response (Figure 11).

5                   The disclosures of each and every publication, patent, and patent application cited herein are hereby incorporated herein by reference in their entirety.

                  While this invention has been disclosed with reference to specific embodiments, it is apparent that other embodiments and variations of this invention may be devised by others skilled in the art without departing from the true spirit and  
10               scope of the invention. The appended claims are intended to be construed to include all such embodiments and equivalent variations.

What is claimed is:

1. A method of eliciting a T cell immune response to an antigen in a mammal comprising administering to said mammal an auxotrophic attenuated strain of *Listeria* which expresses said antigen, wherein said auxotrophic attenuated strain comprises a mutation in at least one gene whose protein product is essential for growth of said *Listeria*.
2. The method of claim 1, wherein said *Listeria* is *L. monocytogenes*.
3. The method of claim 1, wherein said auxotrophic attenuated strain is auxotrophic for the synthesis of D-alanine.
4. The method of claim 3, wherein said mutation comprises a mutation in both the *dal* and the *dat* genes of said *Listeria*.
5. The method of claim 1, wherein said auxotrophic attenuated strain further comprises DNA encoding a heterologous antigen.
6. The method of claim 1, wherein said auxotrophic attenuated strain further comprises a vector comprising a DNA encoding a heterologous antigen.
7. The method of claim 5, wherein said heterologous antigen is an HIV-1 antigen.
8. The method of claim 6, wherein said heterologous antigen is an HIV-1 antigen.

9. A vaccine comprising an auxotrophic attenuated strain of *Listeria* which expresses an antigen, wherein said auxotrophic attenuated strain comprises a mutation in at least one gene whose protein product is essential for growth of said *Listeria*.
10. The vaccine of claim 9, wherein said *Listeria* is *L. monocytogenes*.
11. The vaccine of claim 9, wherein said auxotrophic attenuated strain is auxotrophic for the synthesis of D-alanine.
12. The vaccine of claim 11, wherein said mutation comprises a mutation in both the *dal* and the *dat* genes of said *Listeria*.
13. The vaccine of claim 9, wherein said auxotrophic attenuated strain further comprises DNA encoding a heterologous antigen.
14. The vaccine of claim 9, wherein said auxotrophic attenuated strain further comprises a vector comprising a DNA encoding a heterologous antigen.
15. The vaccine of claim 13, wherein said heterologous antigen is an HIV-1 antigen.
16. The vaccine of claim 15, wherein said heterologous antigen is an HIV-1 antigen.
17. An isolated nucleic acid sequence comprising a portion of a *Listeria dal* gene.

18. An isolated nucleic acid sequence comprising a portion of a *Listeria dat* gene.

19. An isolated strain of *Listeria* comprising a mutation in a *dal* gene and a mutation in a *dat* gene which render said strain auxotrophic for D-alanine.

20. The isolated strain of *Listeria* of claim 19, further comprising a heterologous antigen.

1/17

```

                                30
      *      *      *      *      *      *      *      *      *
ATG GTG ACA GGC TGG CAT CGT CCA ACA TGG ATT GAA ATA GAC CGC GCA
Met Val Thr Gly Trp His Arg Pro Thr Trp Ile Glu Ile Asp Arg Ala

                                60
      *      *      *      *      *      *      *      *      *
GCA ATT CGC GAA AAT ATA AAA AAT GAA CAA AAT AAA CTC CCG GAA AGT
Ala Ile Arg Glu Asn Ile Lys Asn Glu Gln Asn Lys Leu Pro Glu Ser

                                120
      *      *      *      *      *      *      *      *      *
GTC GAC TTA TGG GCA GTA GTC AAA GCT AAT GCA TAT GGT CAC GGA ATT
Val Asp Leu Trp Ala Val Val Lys Ala Asn Ala Tyr Gly His Gly Ile

                                150
      *      *      *      *      *      *      *      *      *
ATC GAA GTT GCT AGG ACG GCG AAA GAA GCT GGA GCA AAA GGT TTC TGC
Ile Glu Val Ala Arg Thr Ala Lys Glu Ala Gly Ala Lys Gly Phe Cys

                                180
      *      *      *      *      *      *      *      *      *
GTA GCC ATT TTA GAT GAG GCA CTG GCT CTT AGA GAA GCT GGA TTT CAA
Val Ala Ile Leu Asp Glu Ala Leu Ala Leu Arg Glu Ala Gly Phe Gln

                                210
      *      *      *      *      *      *      *      *      *
GAT GAC TTT ATT CTT GTG CTT GGT GCA ACC AGA AAA GAA GAT GCT AAT
Asp Asp Phe Ile Leu Val Leu Gly Ala Thr Arg Lys Glu Asp Ala Asn

                                240
      *      *      *      *      *      *      *      *      *
CTG GCA GCC AAA AAC CAC ATT TCA CTT ACT GTT TTT AGA GAA GAT TGG
Leu Ala Ala Lys Asn His Ile Ser Leu Thr Val Phe Arg Glu Asp Trp

                                270
      *      *      *      *      *      *      *      *      *
CTA GAG AAT CTA ACG CTA GAA GCA ACA CTT CGA ATT CAT TTA AAA GTA
Leu Glu Asn Leu Thr Leu Glu Ala Thr Leu Arg Ile His Leu Lys Val

                                300
      *      *      *      *      *      *      *      *      *
GAT AGC GGT ATG GGG CGT CTC GGT ATT CGT ACG ACT GAA GAA GCA_CGG
Asp Ser Gly Met Gly Arg Leu Gly Ile Arg Thr Thr Glu Glu Ala Arg
                                330
                                360
                                390
                                420

```

Fig. 1A

2/17

```

                450                                480
      *      *      *      *      *      *      *      *      *      *
CGA ATT GAA GCA ACC AGT ACT AAT GAT CAC CAA TTA CAA CTG GAA GGT
Arg Ile Glu Ala Thr Ser Thr Asn Asp His Gln Leu Gln Leu Glu Gly

                510
      *      *      *      *      *      *      *      *      *
ATT TAC ACG CAT TTT GCA ACA GCC GAC CAG CTA GAA ACT AGT TAT TTT
Ile Tyr Thr His Phe Ala Thr Ala Asp Gln Leu Glu Thr Ser Tyr Phe

                540                                570
      *      *      *      *      *      *      *      *      *
GAA CAA CAA TTA GCT AAG TTC CAA ACG ATT TTA ACG AGT TTA AAA AAA
Glu Gln Gln Leu Ala Lys Phe Gln Thr Ile Leu Thr Ser Leu Lys Lys

                600
      *      *      *      *      *      *      *      *      *
CGA CCA ACT TAT GTT CAT ACA GCC AAT TCA GCT GCT TCA TTG TTA CAG
Arg Pro Thr Tyr Val His Thr Ala Asn Ser Ala Ala Ser Leu Leu Gln

                630                                660
      *      *      *      *      *      *      *      *      *
CCA CAA ATC GGG TTT GAT GCG ATT CGC TTT GGT ATT TCG ATG TAT GGA
Pro Gln Ile Gly Phe Asp Ala Ile Arg Phe Gly Ile Ser Met Tyr Gly

                690                                720
      *      *      *      *      *      *      *      *      *
TTA ACT CCC TCC ACA GAA ATC AAA ACT AGC TTG CCG TTT GAG CTT AAA
Leu Thr Pro Ser Thr Glu Ile Lys Thr Ser Leu Pro Phe Glu Leu Lys

                750
      *      *      *      *      *      *      *      *      *
CCT GCA CTT GCA CTC TAT ACC GAG ATG GTT CAT GTG AAA GAA CTT GCA
Pro Ala Leu Ala Leu Tyr Thr Glu Met Val His Val Lys Glu Leu Ala

                780                                810
      *      *      *      *      *      *      *      *      *
CCA GGC GAT AGC GTT AGC TAC GGA GCA ACT TAT ACA GCA ACA GAG CGA
Pro Gly Asp Ser Val Ser Tyr Gly Ala Thr Tyr Thr Ala Thr Glu Arg

                840
      *      *      *      *      *      *      *      *      *
GAA TGG GTT GCG ACA TTA CCA ATT GGC TAT GCG GAT GGA TTG ATT CGT
Glu Trp Val Ala Thr Leu Pro Ile Gly Tyr Ala Asp Gly Leu Ile Arg

```

Fig. 1B

3/17

```

      870                                900
*      *      *      *      *      *      *      *      *      *
CAT TAC AGT GGT TTC CAT GTT TTA GTA GAC GGT GAA CCA GCT CCA ATC
His Tyr Ser Gly Phe His Val Leu Val Asp Gly Glu Pro Ala Pro Ile

      930                                960
*      *      *      *      *      *      *      *      *      *
ATT GGT CGA GTT TGT ATG GAT CAA ACC ATC ATA AAA CTA CCA CGT GAA
Ile Gly Arg Val Cys Met Asp Gln Thr Ile Ile Lys Leu Pro Arg Glu

      990
*      *      *      *      *      *      *      *      *      *
TTT CAA ACT GGT TCA AAA GTA ACG ATA ATT GGC AAA GAT CAT GGT AAC
Phe Gln Thr Gly Ser Lys Val Thr Ile Ile Gly Lys Asp His Gly Asn

      1020                                1050
*      *      *      *      *      *      *      *      *      *
ACG GTA ACA GCA GAT GAT GCC GCT CAA TAT TTA GAT ACA ATT AAT TAT
Thr Val Thr Ala Asp Asp Ala Ala Gln Tyr Leu Asp Thr Ile Asn Tyr

      1080
*      *      *      *      *      *      *      *      *      *
GAG GTA ACT TGT TTG TTA AAT GAG CGC ATA CCT AGA AAA TAC ATC CAT
Glu Val Thr Cys Leu Leu Asn Glu Arg Ile Pro Arg Lys Tyr Ile His

*
TAG
*
```

Fig. 1C



|         |     |                                     |     |
|---------|-----|-------------------------------------|-----|
| LMDAL   | 1   | •MVTGWHRPTWIEIDRAAIR ENIKNEQNKL PES | 32  |
| BSTDAL  | 1   | ••MNDFHRDTWAEVDLDAIYDNVENLRRLLPDD   | 31  |
| BSUBDAL | 1   | MSTKPEYRDTWAEIDL SAIKENVS NMKKHIGEH | 33  |
| LMDAL   | 33  | VDLWAVVKANAYGHGIIEVARTAKEAGAKGFCV   | 65  |
| BSTDAL  | 32  | THIMAVVKANAYGHGDVQVARTALERGPPP•AV   | 63  |
| BSUBDAL | 34  | VHLMAVEKANAYGHGDAETA KAALDAGASCLAM  | 66  |
| LMDAL   | 66  | AILDEALALREAGFQDDFILVLGATR KEDANLA  | 98  |
| BSTDAL  | 64  | AFLDEALALREKGI EAP•ILVLGASRPADAALA  | 95  |
| BSUBDAL | 67  | AILDEATSLRKKGLKAP•ILVLGAVPPEYVATA   | 98  |
| LMDAL   | 99  | AKNHISLTVFREDWLENL•TL•EA•••TLRI••   | 124 |
| BSTDAL  | 96  | AQQRIALTVFRSDWLEEASALYSG•••PFPIHF   | 125 |
| BSUBDAL | 99  | AEYDVTLTGYSVEWLOEA•AR•HTKKGSL••HF   | 127 |
| LMDAL   | 125 | HLKVDSGMGRLGIRTT EEARRIEATSTNDHQLO  | 157 |
| BSTDAL  | 126 | HLKMDTGMGRLGVKDEEETKRIVALIERHPHFV   | 158 |
| BSUBDAL | 128 | HLKVDTGMNRLGVKTEEEVQNVMAILDRNPRLK   | 160 |
| LMDAL   | 158 | LEGIYTHFATADQLETSYFEQQLAKFQITILTSL  | 190 |
| BSTDAL  | 159 | LEGLYTHFATADEVNTDYFSYQYTRFLHMLEWL   | 191 |
| BSUBDAL | 161 | CKGVFTHFATADEK EERGYFLMQFERFKELIAPL | 193 |
| LMDAL   | 191 | KKRPTYVHTANSAASL•LQPQIGFD AIRFGISM  | 222 |
| BSTDAL  | 192 | PSRPPLVHCANSAASLR•FPDRTFNMVRFGIAM   | 223 |
| BSUBDAL | 194 | PLKNLMVHCANSAAGLRLKKG F•FNAVRFGI GM | 225 |
| LMDAL   | 223 | YGLTPSTEIKTSLPFELKPALALYTEMVHVKEL   | 255 |
| BSTDAL  | 224 | YGLAPSPGIKPLLPYPLKEAFSLHSRLVHVKKL   | 256 |
| BSUBDAL | 226 | YGLRPSADMSDEIPFQLRPAFTLHSTLSHVKLI   | 258 |
| LMDAL   | 256 | APGDSVSYGATYTA TEREWVATLPIGYADGLIR  | 288 |
| BSTDAL  | 257 | QPGEKVSYGATYTAQTEEWIGTIPIGYADG•VR   | 288 |
| BSUBDAL | 259 | RKGESVSYGA EYTA EKDTWIGTVFVGYADGWLR | 291 |

Fig. 2A

5/17

|         |     |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |     |     |     |
|---------|-----|-----|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|-----|-----|-----|
| LMDAL   | 289 | HYS | G | F | H | V | L | V | D | G | E | P | A | P | I | I | G | R | V | C | M | D | Q | T | I | I | K | L | P | R | E | F | 321 |     |     |
| BSTDAL  | 289 | R   | L | Q | H | F | H | V | L | V | D | G | Q | K | A | P | I | V | G | R | I | C | M | D | Q | C | M | I | R | L | P | G | P   | L   | 321 |
| BSUBDAL | 292 | K   | L | K | G | T | D | I | L | V | K | G | K | R | L | K | I | A | G | R | I | C | M | D | Q | F | M | V | E | L | D | Q | E   | Y   | 324 |
| LMDAL   | 322 | Q   | T | G | S | K | V | T | I | I | G | K | D | H | G | N | T | V | T | A | D | D | A | A | Q | Y | L | D | T | I | N | Y | E   | V   | 354 |
| BSTDAL  | 322 | P   | V | G | T | K | V | T | L | I | G | R | Q | G | D | E | V | I | S | I | D | D | V | A | R | H | L | E | T | I | N | Y | E   | V   | 354 |
| BSUBDAL | 325 | P   | P | G | T | K | V | T | L | I | G | R | Q | G | D | E | Y | I | S | M | D | E | I | A | G | R | L | E | T | I | N | Y | E   | V   | 357 |
| LMDAL   | 355 | T   | C | L | L | N | E | R | I | P | R | K | Y | I | H |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |     | 368 |     |
| BSTDAL  | 355 | P   | C | T | I | S | Y | R | V | P | R | I | F | F | R | H | K | R | I | M | E | V | R | N | A | I | G | R | G | E | S | S | A   |     | 386 |
| BSUBDAL | 358 | A   | C | T | I | S | S | R | V | P | R | M | F | L | E | N | G | S | I | M | E | V | R | N | P | L | L | Q | V | N | I | S | N   |     | 389 |

Fig. 2B

6/17

```

                                30
      *      *      *      *      *      *      *      *      *
ATG AAA GTA TTA GTA AAT AAC CAT TTA GTT GAA AGA GAA GAT GCC ACA
M   K   V   L   V   N   N   H   L   V   E   R   E   D   A   T

                                60
      *      *      *      *      *      *      *      *      *
GTT GAC ATT GAA GAC CGC GGA TAT CAG TTT GGT GAT GGT GTA TAT GAA
V   D   I   E   D   R   G   Y   Q   F   G   D   G   V   Y   E

                                120
      *      *      *      *      *      *      *      *      *
GTA GTT CGT CTA TAT AAT GGA AAA TTC TTT ACT TAT AAT GAA CAC ATT
V   V   R   L   Y   N   G   K   F   F   T   Y   N   E   H   I

                                150
      *      *      *      *      *      *      *      *      *
GAT CGC TTA TAT GCT AGT GCA GCA AAA ATT GAC TTA GTT ATT CCT TAT
D   R   L   Y   A   S   A   A   K   I   D   L   V   I   P   Y

                                180
      *      *      *      *      *      *      *      *      *
TCC AAA GAA GAG CTA CGT GAA TTA CTT GAA AAA TTA GTT GCC GAA AAT
S   K   E   E   L   R   E   L   L   E   K   L   V   A   E   N

                                210
      *      *      *      *      *      *      *      *      *
AAT ATC AAT ACA GGG AAT GTC TAT TTA CAA GTG ACT CGT GGT GTT CAA
N   I   N   T   G   N   V   Y   L   Q   V   T   R   G   V   Q

                                240
      *      *      *      *      *      *      *      *      *
AAC CCA CGT AAT CAT GTA ATC CCT GAT GAT TTC CCT CTA GAA GGC GTT
N   P   R   N   H   V   I   P   D   D   F   P   L   E   G   V

                                270
      *      *      *      *      *      *      *      *      *
TTA ACA GCA GCA GCT CGT GAA GTA CCT AGA AAC GAG CGT CAA TTC GTT
L   T   A   A   A   R   E   V   P   R   N   E   R   Q   F   V

                                300
      *      *      *      *      *      *      *      *      *
GAA GGT GGA ACG GCG ATT ACA GAA GAA GAT GTG CGC TGG TTA CGC TGT
E   G   G   T   A   I   T   E   E   D   V   R   W   L   R   C

                                330
      *      *      *      *      *      *      *      *      *
TTA ACA GCA GCA GCT CGT GAA GTA CCT AGA AAC GAG CGT CAA TTC GTT
L   T   A   A   A   R   E   V   P   R   N   E   R   Q   F   V

                                360
      *      *      *      *      *      *      *      *      *
GAA GGT GGA ACG GCG ATT ACA GAA GAA GAT GTG CGC TGG TTA CGC TGT
E   G   G   T   A   I   T   E   E   D   V   R   W   L   R   C

                                390
      *      *      *      *      *      *      *      *      *
GAA GGT GGA ACG GCG ATT ACA GAA GAA GAT GTG CGC TGG TTA CGC TGT
E   G   G   T   A   I   T   E   E   D   V   R   W   L   R   C

                                420
      *      *      *      *      *      *      *      *      *
GAA GGT GGA ACG GCG ATT ACA GAA GAA GAT GTG CGC TGG TTA CGC TGT
E   G   G   T   A   I   T   E   E   D   V   R   W   L   R   C

```

Fig. 3A

7/17

```

                450                                480
      *          *          *          *          *          *          *          *          *
GAT ATT AAG AGC TTA AAC CTT TTA GGA AAT ATT CTA GCA AAA AAT AAA
D   I   K   S   L   N   L   L   G   N   I   L   A   K   N   K

                510
      *          *          *          *          *          *          *          *
GCA CAT CAA CAA AAT GCT TTG GAA GCT ATT TTA CAT CGC GGG GAA CAA
A   H   Q   Q   N   A   L   E   A   I   L   H   R   G   E   Q

                540                                570
      *          *          *          *          *          *          *          *          *
GTA ACA GAA TGT TCT GCT TCA AAC GTT TCT ATT ATT AAA GAT GGT GTA
V   T   E   C   S   A   S   N   V   S   I   I   K   D   G   V

                600
      *          *          *          *          *          *          *          *
TTA TGG ACG CAT GCG GCA GAT AAC TTA ATC TTA AAT GGT ATC ACT CGT
L   W   T   H   A   A   D   N   L   I   L   N   G   I   T   R

                630                                660
      *          *          *          *          *          *          *          *          *
CAA GTT ATC ATT GAT GTT GCG AAA AAG AAT GGC ATT CCT GTT AAA GAA
Q   V   I   I   D   V   A   K   K   N   G   I   P   V   K   E

                690                                720
      *          *          *          *          *          *          *          *          *
GCG GAT TTC ACT TTA ACA GAC CTT CGT GAA GCG GAT GAA GTG TTC ATT
A   D   F   T   L   T   D   L   R   E   A   D   E   V   F   I

                750
      *          *          *          *          *          *          *          *          *
TCA AGT ACA ACT ATT GAA ATT ACA CCT ATT ACG CAT ATT GAC GGA GTT
S   S   T   T   I   E   I   T   P   I   T   H   I   D   G   V

                780                                810
      *          *          *          *          *          *          *          *          *
CAA GTA GCT GAC GGA AAA CGT GGA CCA ATT ACA GCG CAA CTT CAT CAA
Q   V   A   D   G   K   R   G   P   I   T   A   Q   L   H   Q

```

Fig. 3B

8/17

840  
\* \* \* \* \*  
TAT TTT GTA GAA GAA ATC ACT CGT GCA TGT GGC GAA TTA GAG TTT GCA  
Y F V E E I T R A C G E L E F A

870  
\* \*  
AAA TAA  
K \*

**Fig. 3C**

9/17

|         |     |                                    |     |
|---------|-----|------------------------------------|-----|
| LMDAT   | 1   | M•KVLVNNHLVEREDATVDIEDRGYQFGDGVYE  | 32  |
| SHAEDAT | 1   | MTKVFINGEFIDQNEAKVSYEDRGYVFGDGIYE  | 33  |
| BSPHDAT | 1   | MAYSLWNDQIVEEGSITISPEDRGYQFGDGIYE  | 33  |
| BSPDAT  | 1   | MGYTLWNDQIVKDEEVKIDKEDRGYQFGDGVYE  | 33  |
|         |     |                                    |     |
| LMDAT   | 33  | VVRLYNGKFFTYNEHIDRLYASAAKIDLVIPIYS | 65  |
| SHAEDAT | 34  | YIRAYDGLKFTVTEHFERFIRSASEIQQLDLGYT | 66  |
| BSPHDAT | 34  | VIKVYNGHMFTAQEHIDRFYASAEKIRLVIPIYT | 66  |
| BSPDAT  | 34  | VVKVYNGEMFTVNEHIDRLYASAEKIRITIPYT  | 66  |
|         |     |                                    |     |
| LMDAT   | 66  | KEELRELLKLVANNINTGNVYLQVTRGVQNP    | 98  |
| SHAEDAT | 67  | VEELIDVVRELLKVNNIQNGGIYIQATRGV•AP  | 98  |
| BSPHDAT | 67  | KDVLHKLLHDLIEKNLNTGHVYFQITRGT•TS   | 98  |
| BSPDAT  | 67  | KDKFHQLLHELVEKNEINLNTGHYFQVTRGT•SP | 98  |
|         |     |                                    |     |
| LMDAT   | 99  | RNHVIPDDFPLEGVLTAAAREVPRNERQFVEGG  | 131 |
| SHAEDAT | 99  | RNHSFPT•PEVKPVIMAFKSYDRPYDDLNGI    | 130 |
| BSPHDAT | 99  | RNHIFPD•ASVPAVLTGNVKTGERSIENFEKGV  | 130 |
| BSPDAT  | 99  | RAHQFPEN•TVKPVIIIGYTKENPRPLENLEKGV | 130 |
|         |     |                                    |     |
| LMDAT   | 132 | TAITEEDVRWLRCDIKSLNLLGNILAKNKAHQO  | 164 |
| SHAEDAT | 131 | NAATVEDIRWLRCDIKSLNLLGNVLAKEYAVKY  | 163 |
| BSPHDAT | 131 | KATLVEDVRWLRCDIKSLNLLGAVLAKQEA SEK | 163 |
| BSPDAT  | 131 | KATFVEDIRWLRCDIKSLNLLGAVLAKQEAHEK  | 163 |
|         |     |                                    |     |
| LMDAT   | 165 | NALEAILHRGEQVTECSASNVSIIKDGVLWTHA  | 197 |
| SHAEDAT | 164 | NAGEAIQHRGETVTEGASSNVYAIKDGAIYTHP  | 196 |
| BSPHDAT | 164 | GCYEAILHRGDIITECSSANVYGIKDGKLYTHP  | 196 |
| BSPDAT  | 164 | GCYEAILHRNNTVTEGSSSNVFGIKDGIYTHP   | 196 |
|         |     |                                    |     |
| LMDAT   | 198 | ADNLILNGITRQVIIDVAKKNGIPVKEADFTLT  | 230 |
| SHAEDAT | 197 | VNNYILNGITRQVIKWI SEDEDIPFKEETFTVE | 229 |
| BSPHDAT | 197 | ANNYILNGITRQVILKCAEINLPVIEEPMTKG   | 229 |
| BSPDAT  | 197 | ANNMILKGITRDVVIACANEINMPVKEIPEFTTH | 229 |

Fig. 4A

10/17

|         |     |                                   |     |
|---------|-----|-----------------------------------|-----|
| LMDAT   | 231 | DLREADEVFISSTTIEITPITHIDGVQVADGKR | 263 |
| SHAEDAT | 230 | FLKNADEVIVSSTSAEVTPVVKIDGEQVGDGKV | 262 |
| BSPHDAT | 230 | DLLTMDEIIVSSVSSEVTPVIDVDGQQIGAGVP | 262 |
| BSPDAT  | 230 | EALKMDELFVTSTSEITPVIEIDGKLIRDGKV  | 262 |
| LMDAT   | 264 | GPITAQLHQYFVEEITRACGELEFAK        | 289 |
| SHAEDAT | 263 | GPVTRQLQEGFNKYIESRSS              | 282 |
| BSPHDAT | 263 | GEWTRKLQKAFEAKLPISINA             | 283 |
| BSPDAT  | 263 | GEWTRKLQKOFETKIPKPLHI             | 283 |

Fig. 4B

11/17




Fig. 5



12/17




FIG. 6

13/17




Fig. 7A




Fig. 7B




Fig. 7C

14/17




FIG.8




Fig. 9

16/17




Fig. 10

17/17




Fig. 11A




Fig. 11B

SEQUENCE LISTING

<110> Frankel, Fred R.  
Portnoy, Daniel A.

<120> BACTERIAL VACCINE VECTOR AND METHODS OF USE THEREOF

<130> 9596-51PC

<140> NOT YET ASSIGNED

<141> 1998-11-13

<150> 08/972,902

<151> 1997-11-18

<160> 9

<170> PatentIn Ver. 2.0

<210> 1

<211> 1107

<212> DNA

<213> *Listeria monocytogenes*

<400> 1

```

atggtgacag gctggcatcg tccaacatgg attgaaatag accggcgagc aattcgcgaa 60
aatataaaaa atgaacaaaa taaactcccc gaaagtgtcg acttatgggc agtagtcaaa 120
gctaattgcat atggctcacgg aattatcgaa gttgctagga cggcgaaga agctggagca 180
aaaggtttct gcgtagccat tttagatgag gcactggctc ttagagaagc tggatttcaa 240
gatgacttta ttcttgtgct tggtgcaacc agaaaagaag atgctaactc ggcagccaaa 300
aaccacattt cacttactgt ttttagagaa gattggctag agaactaac gctagaagca 360
acacttcgaa ttcatttaaa agtagatagc ggtatggggc gtctcggtat tcgtacgact 420
gaagaagcac ggcgaaattga agcaaccagt actaatgac accaattaca actggaaggt 480
atttacacgc attttgcaac agccgaccag ctagaaacta gttattttga acaacaatta 540
gctaagttcc aaacgatttt aacgagttta aaaaaacgac caacttatgt tcatacagcc 600
aattcagctg cttcattggt acagccacaa atcggggttg atgcgattcg ctttggtatt 660
tcgatgtatg gattaactcc ctccacagaa atcaaaacta gcttgccggt tgagcttaaa 720
cctgcacttg cactctatac cgagatgggt catgtgaaag aacttgcacc aggcgatagc 780
gtttagctacg gagcaactta tacagcaaca gagcgagaat gggttgagc attaccaatt 840
ggctatgagg atggattgat tcgtcattac agtggtttcc atgttttagt agacgggtgaa 900
ccagctccaa tcattggtcg agtttgtatg gatcaaacca tcataaaact accacgtgaa 960
tttcaaactg gttcaaaagt aacgataatt ggcaaagatc atggtaacac ggtaacagca 1020
gatgatgccg ctcaatattt agatacaatt aattatgagg taacttggtt gttaaatgag 1080
cgcataccta gaaaatacat ccattag                                     1107
    
```

<210> 2

<211> 368

<212> PRT

<213> *Listeria monocytogenes*

&lt;400&gt; 2

Met Val Thr Gly Trp His Arg Pro Thr Trp Ile Glu Ile Asp Arg Ala  
 1 5 10 15  
 Ala Ile Arg Glu Asn Ile Lys Asn Glu Gln Asn Lys Leu Pro Glu Ser  
 20 25 30  
 Val Asp Leu Trp Ala Val Val Lys Ala Asn Ala Tyr Gly His Gly Ile  
 35 40 45  
 Ile Glu Val Ala Arg Thr Ala Lys Glu Ala Gly Ala Lys Gly Phe Cys  
 50 55 60  
 Val Ala Ile Leu Asp Glu Ala Leu Ala Leu Arg Glu Ala Gly Phe Gln  
 65 70 75 80  
 Asp Asp Phe Ile Leu Val Leu Gly Ala Thr Arg Lys Glu Asp Ala Asn  
 85 90 95  
 Leu Ala Ala Lys Asn His Ile Ser Leu Thr Val Phe Arg Glu Asp Trp  
 100 105 110  
 Leu Glu Asn Leu Thr Leu Glu Ala Thr Leu Arg Ile His Leu Lys Val  
 115 120 125  
 Asp Ser Gly Met Gly Arg Leu Gly Ile Arg Thr Thr Glu Glu Ala Arg  
 130 135 140  
 Arg Ile Glu Ala Thr Ser Thr Asn Asp His Gln Leu Gln Leu Glu Gly  
 145 150 155 160  
 Ile Tyr Thr His Phe Ala Thr Ala Asp Gln Leu Glu Thr Ser Tyr Phe  
 165 170 175  
 Glu Gln Gln Leu Ala Lys Phe Gln Thr Ile Leu Thr Ser Leu Lys Lys  
 180 185 190  
 Arg Pro Thr Tyr Val His Thr Ala Asn Ser Ala Ala Ser Leu Leu Gln  
 195 200 205  
 Pro Gln Ile Gly Phe Asp Ala Ile Arg Phe Gly Ile Ser Met Tyr Gly  
 210 215 220  
 Leu Thr Pro Ser Thr Glu Ile Lys Thr Ser Leu Pro Phe Glu Leu Lys  
 225 230 235 240



Pro Ala Leu Ala Leu Tyr Thr Glu Met Val His Val Lys Glu Leu Ala  
 245 250 255

Pro Gly Asp Ser Val Ser Tyr Gly Ala Thr Tyr Thr Ala Thr Glu Arg  
 260 265 270

Glu Trp Val Ala Thr Leu Pro Ile Gly Tyr Ala Asp Gly Leu Ile Arg  
 275 280 285

His Tyr Ser Gly Phe His Val Leu Val Asp Gly Glu Pro Ala Pro Ile  
 290 295 300

Ile Gly Arg Val Cys Met Asp Gln Thr Ile Ile Lys Leu Pro Arg Glu  
 305 310 315 320

Phe Gln Thr Gly Ser Lys Val Thr Ile Ile Gly Lys Asp His Gly Asn  
 325 330 335

Thr Val Thr Ala Asp Asp Ala Ala Gln Tyr Leu Asp Thr Ile Asn Tyr  
 340 345 350

Glu Val Thr Cys Leu Leu Asn Glu Arg Ile Pro Arg Lys Tyr Ile His  
 355 360 365

<210> 3

<211> 386

<212> PRT

<213> *Listeria monocytogenes*

<400> 3

Met Asn Asp Phe His Arg Asp Thr Trp Ala Glu Val Asp Leu Asp Ala  
 1 5 10 15

Ile Tyr Asp Asn Val Glu Asn Leu Arg Arg Leu Leu Pro Asp Asp Thr  
 20 25 30

His Ile Met Ala Val Val Lys Ala Asn Ala Tyr Gly His Gly Asp Val  
 35 40 45

Gln Val Ala Arg Thr Ala Leu Glu Arg Gly Pro Pro Pro Ala Val Ala  
 50 55 60

Phe Leu Asp Glu Ala Leu Ala Leu Arg Glu Lys Gly Ile Glu Ala Pro  
 65 70 75 80

Ile Leu Val Leu Gly Ala Ser Arg Pro Ala Asp Ala Ala Leu Ala Ala  
 85 90 95

Gln Gln Arg Ile Ala Leu Thr Val Phe Arg Ser Asp Trp Leu Glu Glu  
 100 105 110

Ala Ser Ala Leu Tyr Ser Gly Pro Phe Pro Ile His Phe His Leu Lys  
 115 120 125

Met Asp Thr Gly Met Gly Arg Leu Gly Val Lys Asp Glu Glu Glu Thr  
 130 135 140

Lys Arg Ile Val Ala Leu Ile Glu Arg His Pro His Phe Val Leu Glu  
 145 150 155 160

Gly Leu Tyr Thr His Phe Ala Thr Ala Asp Glu Val Asn Thr Asp Tyr  
 165 170 175

Phe Ser Tyr Gln Tyr Thr Arg Phe Leu His Met Leu Glu Trp Leu Pro  
 180 185 190

Ser Arg Pro Pro Leu Val His Cys Ala Asn Ser Ala Ala Ser Leu Arg  
 195 200 205

Phe Pro Asp Arg Thr Phe Asn Met Val Arg Phe Gly Ile Ala Met Tyr  
 210 215 220

Gly Leu Ala Pro Ser Pro Gly Ile Lys Pro Leu Leu Pro Tyr Pro Leu  
 225 230 235 240

Lys Glu Ala Phe Ser Leu His Ser Arg Leu Val His Val Lys Lys Leu  
 245 250 255

Gln Pro Gly Glu Lys Val Ser Tyr Gly Ala Thr Tyr Thr Ala Gln Thr  
 260 265 270

Glu Glu Trp Ile Gly Thr Ile Pro Ile Gly Tyr Ala Asp Gly Val Arg  
 275 280 285

Arg Leu Gln His Phe His Val Leu Val Asp Gly Gln Lys Ala Pro Ile  
 290 295 300

Val Gly Arg Ile Cys Met Asp Gln Cys Met Ile Arg Leu Pro Gly Pro  
 305 310 315 320

Leu Pro Val Gly Thr Lys Val Thr Leu Ile Gly Arg Gln Gly Asp Glu  
 325 330 335

Val Ile Ser Ile Asp Asp Val Ala Arg His Leu Glu Thr Ile Asn Tyr  
 340 345 350

Glu Val Pro Cys Thr Ile Ser Tyr Arg Val Pro Arg Ile Phe Phe Arg  
 355 360 365

His Lys Arg Ile Met Glu Val Arg Asn Ala Ile Gly Arg Gly Glu Ser  
 370 375 380

Ser Ala  
 385

<210> 4

<211> 389

<212> PRT

<213> *Listeria monocytogenes*

<400> 4

Met Ser Thr Lys Pro Phe Tyr Arg Asp Thr Trp Ala Glu Ile Asp Leu  
 1 5 10 15

Ser Ala Ile Lys Glu Asn Val Ser Asn Met Lys Lys His Ile Gly Glu  
 20 25 30

His Val His Leu Met Ala Val Glu Lys Ala Asn Ala Tyr Gly His Gly  
 35 40 45

Asp Ala Glu Thr Ala Lys Ala Ala Leu Asp Ala Gly Ala Ser Cys Leu  
 50 55 60

Ala Met Ala Ile Leu Asp Glu Ala Ile Ser Leu Arg Lys Lys Gly Leu  
 65 70 75 80

Lys Ala Pro Ile Leu Val Leu Gly Ala Val Pro Pro Glu Tyr Val Ala  
 85 90 95

Ile Ala Ala Glu Tyr Asp Val Thr Leu Thr Gly Tyr Ser Val Glu Trp  
 100 105 110

Leu Gln Glu Ala Ala Arg His Thr Lys Lys Gly Ser Leu His Phe His  
 115 120 125

Leu Lys Val Asp Thr Gly Met Asn Arg Leu Gly Val Lys Thr Glu Glu  
 130 135 140

Glu Val Gln Asn Val Met Ala Ile Leu Asp Arg Asn Pro Arg Leu Lys

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| 145 |     |     |     |     | 150 |     |     |     |     |     | 155 |     |     |     |     | 160 |
| Cys | Lys | Gly | Val | Phe | Thr | His | Phe | Ala | Thr | Ala | Asp | Glu | Lys | Glu | Arg |     |
|     |     |     |     | 165 |     |     |     |     | 170 |     |     |     |     |     | 175 |     |
| Gly | Tyr | Phe | Leu | Met | Gln | Phe | Glu | Arg | Phe | Lys | Glu | Leu | Ile | Ala | Pro |     |
|     |     |     | 180 |     |     |     |     | 185 |     |     |     |     |     | 190 |     |     |
| Leu | Pro | Leu | Lys | Asn | Leu | Met | Val | His | Cys | Ala | Asn | Ser | Ala | Ala | Gly |     |
|     |     | 195 |     |     |     |     | 200 |     |     |     |     | 205 |     |     |     |     |
| Leu | Arg | Leu | Lys | Lys | Gly | Phe | Phe | Asn | Ala | Val | Arg | Phe | Gly | Ile | Gly |     |
|     | 210 |     |     |     |     | 215 |     |     |     |     | 220 |     |     |     |     |     |
| Met | Tyr | Gly | Leu | Arg | Pro | Ser | Ala | Asp | Met | Ser | Asp | Glu | Ile | Pro | Phe |     |
| 225 |     |     |     |     | 230 |     |     |     |     | 235 |     |     |     |     | 240 |     |
| Gln | Leu | Arg | Pro | Ala | Phe | Thr | Leu | His | Ser | Thr | Leu | Ser | His | Val | Lys |     |
|     |     |     |     | 245 |     |     |     |     | 250 |     |     |     |     |     | 255 |     |
| Leu | Ile | Arg | Lys | Gly | Glu | Ser | Val | Ser | Tyr | Gly | Ala | Glu | Tyr | Thr | Ala |     |
|     |     |     | 260 |     |     |     |     | 265 |     |     |     |     |     | 270 |     |     |
| Glu | Lys | Asp | Thr | Trp | Ile | Gly | Thr | Val | Pro | Val | Gly | Tyr | Ala | Asp | Gly |     |
|     |     | 275 |     |     |     |     | 280 |     |     |     |     |     |     | 285 |     |     |
| Trp | Leu | Arg | Lys | Leu | Lys | Gly | Thr | Asp | Ile | Leu | Val | Lys | Gly | Lys | Arg |     |
|     | 290 |     |     |     |     | 295 |     |     |     |     |     | 300 |     |     |     |     |
| Leu | Lys | Ile | Ala | Gly | Arg | Ile | Cys | Met | Asp | Gln | Phe | Met | Val | Glu | Leu |     |
| 305 |     |     |     |     | 310 |     |     |     |     | 315 |     |     |     |     | 320 |     |
| Asp | Gln | Glu | Tyr | Pro | Pro | Gly | Thr | Lys | Val | Thr | Leu | Ile | Gly | Arg | Gln |     |
|     |     |     |     | 325 |     |     |     |     | 330 |     |     |     |     |     | 335 |     |
| Gly | Asp | Glu | Tyr | Ile | Ser | Met | Asp | Glu | Ile | Ala | Gly | Arg | Leu | Glu | Thr |     |
|     |     |     | 340 |     |     |     |     | 345 |     |     |     |     | 350 |     |     |     |
| Ile | Asn | Tyr | Glu | Val | Ala | Cys | Thr | Ile | Ser | Ser | Arg | Val | Pro | Arg | Met |     |
|     | 355 |     |     |     |     |     | 360 |     |     |     |     |     | 365 |     |     |     |
| Phe | Leu | Glu | Asn | Gly | Ser | Ile | Met | Glu | Val | Arg | Asn | Pro | Leu | Leu | Gln |     |
|     | 370 |     |     |     |     |     | 375 |     |     |     | 380 |     |     |     |     |     |
| Val | Asn | Ile | Ser | Asn |     |     |     |     |     |     |     |     |     |     |     |     |
| 385 |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |

<210> 5  
 <211> 870  
 <212> DNA  
 <213> *Listeria monocytogenes*

<400> 5  
 atgaaagtat tagtaaataa ccatttagtt gaaagagaag atgccacagt tgacattgaa 60  
 gaccgcgat atcagtttgg tgatggtgta tatgaagtag ttcgtctata taatggaaaa 120  
 ttctttactt ataatgaaca cattgatcgc ttatatgcta gtgcagcaaa aattgactta 180  
 gttattcctt attccaaaga agagctacgt gaattacttg aaaaattagt tgccgaaaat 240  
 aatatcaata cagggaatgt ctatttacia gtgactcgtg gtgttcaaaa cccacgtaat 300  
 catgtaatcc ctgatgattt ccctctagaa ggcgttttaa cagcagcagc tcgtgaagta 360  
 cctagaaacg agcgtcaatt cgttgaaggt ggaacggcga ttacagaaga agatgtgctc 420  
 tggttacgct gtgatattaa gagcttaaac cttttaggaa atattctagc aaaaaataaa 480  
 gcacatcaac aaaatgcttt ggaagctatt ttacatcgcg gggaacaagt aacagaatgt 540  
 tctgcttcaa acgtttctat tattaagat ggtgtattat ggacgcatgc ggcagataac 600  
 ttaatcttaa atggtatcac tcgtcaagtt atcattgatg ttgcgaaaaa gaatggcatt 660  
 cctgttaaag aagcggattt cactttaaca gaccttcgtg aagcggatga agtgttcatt 720  
 tcaagtacia ctattgaaat tacacctatt acgcatattg acggagttca agtagctgac 780  
 ggaaaacgtg gaccaattac agcgcaactt catcaatatt ttgtagaaga aatcactcgt 840  
 gcatgtggcg aattagagtt tgcaaaataa 870

<210> 6  
 <211> 289  
 <212> PRT  
 <213> *Listeria monocytogenes*

<400> 6  
 Met Lys Val Leu Val Asn Asn His Leu Val Glu Arg Glu Asp Ala Thr  
 1 5 10 15  
 Val Asp Ile Glu Asp Arg Gly Tyr Gln Phe Gly Asp Gly Val Tyr Glu  
 20 25 30  
 Val Val Arg Leu Tyr Asn Gly Lys Phe Phe Thr Tyr Asn Glu His Ile  
 35 40 45  
 Asp Arg Leu Tyr Ala Ser Ala Ala Lys Ile Asp Leu Val Ile Pro Tyr  
 50 55 60  
 Ser Lys Glu Glu Leu Arg Glu Leu Leu Glu Lys Leu Val Ala Glu Asn  
 65 70 75 80  
 Asn Ile Asn Thr Gly Asn Val Tyr Leu Gln Val Thr Arg Gly Val Gln  
 85 90 95  
 Asn Pro Arg Asn His Val Ile Pro Asp Asp Phe Pro Leu Glu Gly Val  
 100 105 110

Leu Thr Ala Ala Ala Arg Glu Val Pro Arg Asn Glu Arg Gln Phe Val  
 115 120 125

Glu Gly Gly Thr Ala Ile Thr Glu Glu Asp Val Arg Trp Leu Arg Cys  
 130 135 140

Asp Ile Lys Ser Leu Asn Leu Leu Gly Asn Ile Leu Ala Lys Asn Lys  
 145 150 155 160

Ala His Gln Gln Asn Ala Leu Glu Ala Ile Leu His Arg Gly Glu Gln  
 165 170 175

Val Thr Glu Cys Ser Ala Ser Asn Val Ser Ile Ile Lys Asp Gly Val  
 180 185 190

Leu Trp Thr His Ala Ala Asp Asn Leu Ile Leu Asn Gly Ile Thr Arg  
 195 200 205

Gln Val Ile Ile Asp Val Ala Lys Lys Asn Gly Ile Pro Val Lys Glu  
 210 215 220

Ala Asp Phe Thr Leu Thr Asp Leu Arg Glu Ala Asp Glu Val Phe Ile  
 225 230 235 240

Ser Ser Thr Thr Ile Glu Ile Thr Pro Ile Thr His Ile Asp Gly Val  
 245 250 255

Gln Val Ala Asp Gly Lys Arg Gly Pro Ile Thr Ala Gln Leu His Gln  
 260 265 270

Tyr Phe Val Glu Glu Ile Thr Arg Ala Cys Gly Glu Leu Glu Phe Ala  
 275 280 285

Lys

<210> 7  
 <211> 282  
 <212> PRT  
 <213> *Listeria monocytogenes*

<400> 7  
 Met Thr Lys Val Phe Ile Asn Gly Glu Phe Ile Asp Gln Asn Glu Ala  
 1 5 10 15

Lys Val Ser Tyr Glu Asp Arg Gly Tyr Val Phe Gly Asp Gly Ile Tyr

|   |    |     |    |     |    |     |
|---|----|-----|----|-----|----|-----|
|   | 20 |     | 25 |     | 30 |     |
| Glu Tyr Ile Arg Ala Tyr Asp Gly Lys Leu Phe Thr Val Thr Glu His | 35 |     | 40 |     | 45 |     |
| Phe Glu Arg Phe Ile Arg Ser Ala Ser Glu Ile Gln Leu Asp Leu Gly | 50 |     | 55 |     | 60 |     |
| Tyr Thr Val Glu Glu Leu Ile Asp Val Val Arg Glu Leu Leu Lys Val | 65 |     | 70 |     | 75 | 80  |
| Asn Asn Ile Gln Asn Gly Gly Ile Tyr Ile Gln Ala Thr Arg Gly Val |    | 85  |    | 90  |    | 95  |
| Ala Pro Arg Asn His Ser Phe Pro Thr Pro Glu Val Lys Pro Val Ile |    | 100 |    | 105 |    | 110 |
| Met Ala Phe Ala Lys Ser Tyr Asp Arg Pro Tyr Asp Asp Leu Glu Asn |    | 115 |    | 120 |    | 125 |
| Gly Ile Asn Ala Ala Thr Val Glu Asp Ile Arg Trp Leu Arg Cys Asp |    | 130 |    | 135 |    | 140 |
| Ile Lys Ser Leu Asn Leu Leu Gly Asn Val Leu Ala Lys Glu Tyr Ala |    | 145 |    | 150 |    | 155 |
| Val Lys Tyr Asn Ala Gly Glu Ala Ile Gln His Arg Gly Glu Thr Val |    | 165 |    | 170 |    | 175 |
| Thr Glu Gly Ala Ser Ser Asn Val Tyr Ala Ile Lys Asp Gly Ala Ile |    | 180 |    | 185 |    | 190 |
| Tyr Thr His Pro Val Asn Asn Tyr Ile Leu Asn Gly Ile Thr Arg Lys |    | 195 |    | 200 |    | 205 |
| Val Ile Lys Trp Ile Ser Glu Asp Glu Asp Ile Pro Phe Lys Glu Glu |    | 210 |    | 215 |    | 220 |
| Thr Phe Thr Val Glu Phe Leu Lys Asn Ala Asp Glu Val Ile Val Ser |    | 225 |    | 230 |    | 235 |
| Ser Thr Ser Ala Glu Val Thr Pro Val Val Lys Ile Asp Gly Glu Gln |    | 245 |    | 250 |    | 255 |
| Val Gly Asp Gly Lys Val Gly Pro Val Thr Arg Gln Leu Gln Glu Gly |    | 260 |    | 265 |    | 270 |
| Phe Asn Lys Tyr Ile Glu Ser Arg Ser Ser                         |    |     |    |     |    |     |

275

280

<210> 8

<211> 283

<212> PRT

<213> *Listeria monocytogenes*

<400> 8

Met Ala Tyr Ser Leu Trp Asn Asp Gln Ile Val Glu Glu Gly Ser Ile  
 1 5 10 15

Thr Ile Ser Pro Glu Asp Arg Gly Tyr Gln Phe Gly Asp Gly Ile Tyr  
 20 25 30

Glu Val Ile Lys Val Tyr Asn Gly His Met Phe Thr Ala Gln Glu His  
 35 40 45

Ile Asp Arg Phe Tyr Ala Ser Ala Glu Lys Ile Arg Leu Val Ile Pro  
 50 55 60

Tyr Thr Lys Asp Val Leu His Lys Leu Leu His Asp Leu Ile Glu Lys  
 65 70 75 80

Asn Asn Leu Asn Thr Gly His Val Tyr Phe Gln Ile Thr Arg Gly Thr  
 85 90 95

Thr Ser Arg Asn His Ile Phe Pro Asp Ala Ser Val Pro Ala Val Leu  
 100 105 110

Thr Gly Asn Val Lys Thr Gly Glu Arg Ser Ile Glu Asn Phe Glu Lys  
 115 120 125

Gly Val Lys Ala Thr Leu Val Glu Asp Val Arg Trp Leu Arg Cys Asp  
 130 135 140

Ile Lys Ser Leu Asn Leu Leu Gly Ala Val Leu Ala Lys Gln Glu Ala  
 145 150 155 160

Ser Glu Lys Gly Cys Tyr Glu Ala Ile Leu His Arg Gly Asp Ile Ile  
 165 170 175

Thr Glu Cys Ser Ser Ala Asn Val Tyr Gly Ile Lys Asp Gly Lys Leu  
 180 185 190

Tyr Thr His Pro Ala Asn Asn Tyr Ile Leu Asn Gly Ile Thr Arg Gln  
 195 200 205



Val Ile Leu Lys Cys Ala Ala Glu Ile Asn Leu Pro Val Ile Glu Glu  
 210 215 220

Pro Met Thr Lys Gly Asp Leu Leu Thr Met Asp Glu Ile Ile Val Ser  
 225 230 235 240

Ser Val Ser Ser Glu Val Thr Pro Val Ile Asp Val Asp Gly Gln Gln  
 245 250 255

Ile Gly Ala Gly Val Pro Gly Glu Trp Thr Arg Lys Leu Gln Lys Ala  
 260 265 270

Phe Glu Ala Lys Leu Pro Ile Ser Ile Asn Ala  
 275 280

<210> 9

<211> 283

<212> PRT

<213> *Listeria monocytogenes*

<400> 9

Met Gly Tyr Thr Leu Trp Asn Asp Gln Ile Val Lys Asp Glu Glu Val  
 1 5 10 15

Lys Ile Asp Lys Glu Asp Arg Gly Tyr Gln Phe Gly Asp Gly Val Tyr  
 20 25 30

Glu Val Val Lys Val Tyr Asn Gly Glu Met Phe Thr Val Asn Glu His  
 35 40 45

Ile Asp Arg Leu Tyr Ala Ser Ala Glu Lys Ile Arg Ile Thr Ile Pro  
 50 55 60

Tyr Thr Lys Asp Lys Phe His Gln Leu Leu His Glu Leu Val Glu Lys  
 65 70 75 80

Asn Glu Leu Asn Thr Gly His Ile Tyr Phe Gln Val Thr Arg Gly Thr  
 85 90 95

Ser Pro Arg Ala His Gln Phe Pro Glu Asn Thr Val Lys Pro Val Ile  
 100 105 110

Ile Gly Tyr Thr Lys Glu Asn Pro Arg Pro Leu Glu Asn Leu Glu Lys  
 115 120 125

Gly Val Lys Ala Thr Phe Val Glu Asp Ile Arg Trp Leu Arg Cys Asp  
 130 135 140

Ile Lys Ser Leu Asn Leu Leu Gly Ala Val Leu Ala Lys Gln Glu Ala  
145 150 155 160

His Glu Lys Gly Cys Tyr Glu Ala Ile Leu His Arg Asn Asn Thr Val  
165 170 175

Thr Glu Gly Ser Ser Ser Asn Val Phe Gly Ile Lys Asp Gly Ile Leu  
180 185 190

Tyr Thr His Pro Ala Asn Asn Met Ile Leu Lys Gly Ile Thr Arg Asp  
195 200 205

Val Val Ile Ala Cys Ala Asn Glu Ile Asn Met Pro Val Lys Glu Ile  
210 215 220

Pro Phe Thr Thr His Glu Ala Leu Lys Met Asp Glu Leu Phe Val Thr  
225 230 235 240

Ser Thr Thr Ser Glu Ile Thr Pro Val Ile Glu Ile Asp Gly Lys Leu  
245 250 255

Ile Arg Asp Gly Lys Val Gly Glu Trp Thr Arg Lys Leu Gln Lys Gln  
260 265 270

Phe Glu Thr Lys Ile Pro Lys Pro Leu His Ile  
275 280

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/24357

|   |   |  |
|---|---|--|
| <b>A. CLASSIFICATION OF SUBJECT MATTER</b><br>IPC(6) : A61K 39/02; C12P 21/06, 21/04; C07H 21/04<br>US CL : 424/200.1, 234.1; 435/69.1, 71.2; 536/23.7<br>According to International Patent Classification (IPC) or to both national classification and IPC   |   |  |
| <b>B. FIELDS SEARCHED</b><br>Minimum documentation searched (classification system followed by classification symbols)<br>U.S. : 424/200.1, 234.1; 435/69.1, 71.2; 536/23.7<br><br>Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched<br><br>Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)<br>USPATFULL, MEDLINE, WPIDS, CA |   |  |
| <b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>   |   |  |
| Category*   | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No.  |
| A,P   | US 5,830,702 A (PORTNOY et al.) 03 November 1998, see entire document.  | 1-20   |
| <input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.   |   |  |
| *<br>*A*<br>*E*<br>*L*<br>*O*<br>*P*  | Special categories of cited documents:<br>document defining the general state of the art which is not considered to be of particular relevance<br>earlier document published on or after the international filing date<br>document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)<br>document referring to an oral disclosure, use, exhibition or other means<br>document published prior to the international filing date but later than the priority date claimed | *T*<br>*X*<br>*Y*<br>*&*   |
|   |   | later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention<br>document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone<br>document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art<br>document member of the same patent family |
| Date of the actual completion of the international search<br>15 FEBRUARY 1999   | Date of mailing of the international search report<br>25 FEB 1999   |  |
| Name and mailing address of the ISA/US<br>Commissioner of Patents and Trademarks<br>Box PCT<br>Washington, D.C. 20231<br>Facsimile No. (703) 305-3230   | Authorized officer<br><i>D. Lawrence Lee</i><br>Jeffrey S. Parkin, Ph.D.<br>Telephone No. (703) 308-0196  |  |